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Abstract 
Investigating the Role of Nuclear Receptors in HIV/HAART-Associated  
Dyslipidemic Lipodystrophy  
Jennifer Berbaum 
Richard K. Harrison, Ph.D. 
 
 
 
 
The use of highly active antiretroviral therapy (HAART) to manage HIV infection 
is associated with the development of HIV/HAART-associated dyslipidemic 
lipodystrophy (HADL). HADL symptoms are comprised of metabolic dysfunctions 
resulting in hyperlipidemia, fat redistribution, and insulin resistance. The direct 
interaction of HIV drugs with nuclear receptors involved in metabolic pathways has been 
largely unexplored. HIV drugs were evaluated for effect on the activation of farsenoid X 
receptor (FXR), liver X receptor alpha (LXRα), retinoid X receptor alpha (RXRα), 
pregnane X receptor (PXR) and the peroxisome proliferator-activated receptor family 
(PPAR α, γ, and δ). Our results indicate direct inhibition of PPARα and PPARγ 
activation by protease inhibitors (PIs) in both coactivator recruitment and reporter gene 
assays. Gene chip analysis demonstrated that saquinavir and ritonavir reduced the 
expression level of PPARγ target genes in primary human hepatocytes. Partial recovery 
of mRNA levels of glucokinase (GK) and GLUT2 was achieved when hepatocytes were 
incubated in combination with the PPARγ agonist troglitazone. Decreased glucose 
sensing capabilities through PI-mediated inhibition of PPARγ activation may be a 
contributing factor in symptoms of HADL. 
PPARα is the nuclear receptor responsible for regulating genes that control lipid 
homeostasis. Because of this role, PPARα has become a target of interest for the 
development of drugs to treat diseases such as dyslipidemia, obesity and atherosclerosis. 
  ix 
Assays currently employed to determine potency and efficacy of potential drug 
candidates typically utilize a truncated form of the native receptor, one which lacks the 
entire N-terminal region of the protein. We report that differences in PPARα full length 
and ligand binding domain constructs result in differences in binding affinity for 
coactivator peptides, but have little effect on potency of agonists in both cell free and cell 
based nuclear receptor assays.   
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Chapter 1: General Introduction 
 
 
 
1.1 HIV/HAART Associated Dyslipidemic Lipodystrophy (HADL) 
1.1.1 Highly Active Antiretroviral Therapy (HAART) 
As of 2005, approximately 40 million people world wide are living with HIV [1]. 
In developed countries, the life expectancy of HIV-infected individuals has increased 
substantially through the implementation of highly active antiretroviral therapy 
(HAART) in the management of HIV infection [2-4]. The effectiveness of HAART lies 
in the co administration of different classes of antiretroviral drugs. These therapies target 
specific mechanisms within the HIV life cycle and provide a means for simultaneous 
inhibition of diverse viral processes providing tighter control of HIV replication than 
could be achieved with single therapy [2]. The three major classes of HIV drugs currently 
employed in HAART are the non-nucleoside reverse transcriptase inhibitors (NNRTIs), 
nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTI and NtRTI) and 
HIV protease inhibitors (PIs) [5].     
 Figure 1 shows the life cycle of HIV infection and illustrates the intervention 
points targeted by each of the three classes of drugs used in HAART. The mechanism of 
action of the NRTI and NtRTIs class of HIV drugs is the inhibition of transcription of 
viral ssRNA into ssDNA , an essential first step for viral dsDNA insertion into the host 
chromosome [6]. NRTI and NtRTIs are designed to structurally resemble the cellular 
nucleotides needed for reverse transcription of viral RNA [7, 8]. These nucleotide 
analogues are incorporated into the elongating strand of viral DNA by HIV reverse 
transcriptase [9]. This drug class does not directly inhibit HIV reverse transcriptase 
  2 
activity but rather inhibits the elongation process itself. Unlike normal cellular 
nucleotides, NRTIs and NtRTIs lack the required 3'-hydroxyl group for addition of 
subsequent nucleotides and causes chain termination once incorporated into the 
elongating DNA strand. Both NRTI and NtRTIs need to be converted to their 
triphosphate form by cellular kinases. NtRTIs are monophosphorylated and require fewer 
metabolic steps to achieve their active form then the NRTI group which requires three 
phosphorylation events. The class of NRTIs currently includes the drugs zidovudine, 
didanosine, zalcitabine, stavudine, lamivudine, abacavir, and emtricitabine. 
     
 Figure 1. Mechanism of Action of HIV Drug Classes. 
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The NNRTI class of drugs also inhibit reverse transcription but do so in a more 
targeted manner than the nucleotide analogue class [6]. NNRTIs bind to a hydrophobic 
pocket located close to the catalytic domain of the HIV reverse transcriptase enzyme 
complex and inhibit the movement of protein domains required during DNA synthesis 
from viral RNA [10, 11]. In addition to target specificity, NNRTIs have an added 
advantage over the NRTI class because they do not need to be processed by cellular 
enzymes to become therapeutically active [8]. The class of NNRTIs is currently 
comprised of nevirapine, delavirdine, efavirenz, and emvirine. 
PIs, the most potent therapeutic agent for HIV treatment, prevent viral replication 
by inhibiting the activity of HIV protease, an enzyme that cleaves nascent viral 
polyproteins for final assembly of new virons [12-14]. This critical process occurs as new 
virions bud from the membrane of an HIV-infected cell and continues after the immature 
virus is released. If the polyproteins are not cleaved, the virus fails to mature and is 
incapable of infecting a new cell. Five PIs, ritonavir, saquinavir, indinavir, atazanavir and 
nelfinavir are currently available for use in HAART. 
HAART has extended the lives of HIV positive people far beyond what could 
have been hoped for prior to large scale implementation of the therapy in 1995. Despite 
the benefits of HAART, acute adverse events often reduce patient compliance and limit 
the effectiveness of treatment [15, 16]. Within the first year of treatment, ~50% of 
patients will modify or discontinue HAART altogether [16]. Among the side effects cited 
for discontinuation or modifications to HAART regimen are persistent diarrhea and 
nausea with significant weight loss, anemia, psychosis, renal failure, lactic acidosis, 
pancreatitis, polyneuropathy and hepatotoxicity [16, 17]. Patients who can adjust to 
  4 
HAART must remain on a cocktail of HIV drugs for the duration of their lives in order to 
maintain low viral titer. Long-term use of HAART presents additional problems for HIV 
patients. Continuous long-term use of HAART has been linked to development of a 
metabolic disorder known as HIV/HAART associated dyslipidemic lipodystrophy. [18, 
19].  
 
1.1.2 Symptoms & Health Risks 
Lipodystrophy, in patient with HIV, was first described in 1998 by Carr et al., 
approximately three years after PIs were employed in HIV treatment and HAART 
became the standard of care [20]. HIV/HAART associated dyslipidemic lipodystrophy 
(HADL) is used to describe a complex assembly of physical and metabolic abnormalities 
directly associated with the use of HAART in the treatment of HIV infection [19]. In 
general, HADL is indicated when HIV patients present with a combination of the 
following: elevated total cholesterol (> 200 mg / dL) combined with a decrease in high 
density lipoprotein (HDL) levels, increased triglycerides (> 325 mg / dL), insulin 
resistance and changes in body fat distribution with increased truncal obesity [20, 21]. 
Manifestation of HADL metabolic symptoms are considered to be significant risk factors 
for developing cardiovascular disease and type 2 diabetes [22-24].  
The first report of body fat redistribution in an HIV patient was described in 1997 
preceding the description of associated metabolic effects a year later [18, 25]. The main 
clinical features described involve the loss of subcutaneous adipose from the face and 
extremities resulting in an overly muscular appearance with prominent veins and sunken 
facial features. In conjunction with the loss of peripheral adipose, patients also have 
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excess deposition of adipose in tissues around the neck (double chin), dorsocervical spine 
(buffalo hump) and intrabdominal region [26, 27]. While these physical changes are often 
associated with successful reduction of viral burden and elevated CD4 counts, these 
changes also carry social stigma by presenting an outward sign of a patients HIV status 
[26, 28]. The appearance-related side effects have a profound psychological effect on 
patients and have been shown to impact long-term compliance to treatment [29-31]. In 
addition to representing HIV status, a shift from subcutaneous to visceral adipose 
accumulation also represents an underlying dysfunction in metabolic processes.  
Visceral adipose is, metabolically speaking, more active than subcutaneous 
adipose [32]. Gene expression and cytokine release of negative effectors of metabolism 
such as resistin from visceral adipose is more robust in response to nutrient intake than 
levels found in subcutaneous adipose [33]. Visceral adipose is less responsive to the 
antilipolytic effects of insulin and as a result releases more free fatty acids (FFA) and 
cortisol into circulation than subcutaneous. High FFA and cortisol levels have powerful 
combined effects, resulting in insulin resistance and increased hepatic gluconeogenesis. 
Removal of visceral adipose has been shown to reverse peripheral and hepatic insulin 
resistance providing a direct link between the site of fat storage and the risk of 
developing insulin resistance, diabetes and dyslipidemia [34]. 
Dyslipidemia in HADL is characterized by increased levels of triglycerides 
(hypertriglyceremia) and cholesterol (hypercholesterolemia) with low levels of HDL and 
increased levels of low density lipoprotein (LDL). It has been well established that 
dyslipidemia is a significant risk factor for developing coronary artery disease (CAD) 
[35]. LDL particles are generated from very low density lipoproteins (VLDLs) which are 
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secreted from the liver and carry excess hepatic cholesterol and triglycerides (TG) to 
peripheral organs for use as energy or for storage [36]. The action of lipoprotein lipases 
on cell surfaces strip the VLDL of TGs resulting in formation of intermediate density 
lipoproteins (IDLs). These particles are taken up by the liver or converted to LDL by 
hepatic lipase which further strip the IDL of TGs creating a predominantly cholesterol 
laden particle.  One of the first steps in the development of CAD is the movement of LDL 
into the arterial wall and the chemical modification and oxidation of LDL lipids [37]. 
Oxidized LDL (oxLDL) stimulates inflammatory signaling and recruitment of monocytes 
into the arterial wall. The monocytes differentiate into macrophages and internalize 
oxLDL. Loading of machrophages with oxLDL transforms these cells into foam cells.  
Foam cells are enlarged and filled with lipids that are released into the arterial wall 
during cell lysis forming the foundation of atherogenic plaques.  
HDL is known as the good component in total cholesterol because of it role in 
reverse cholesterol transport [38]. Whereas the role of LDL is to transport excess 
cholesterol and triglycerides from the liver to peripheral tissues, HDL transfers 
cholesterol from the peripheral tissues back to the liver for excretion as bile acids. This 
transport is accomplished through the exchange of cholesterol from cells to HDL through 
the interaction of  ATP binding cassette A1 transporters (ABCA1) on cell surfaces and 
apolipoprotein-AI proteins within the HDL particle [36, 39].  Decreased HDL levels 
accelerate progression of CAD because of a reduction in cholesterol deloading of 
macrophages. Even after arterial lesions have been established, increasing HDL levels 
has been shown to reduce the size and number of lesion in both mice and humans 
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indicating that HDL levels may be more important in CAD risk than total cholesterol and 
LDL levels [40, 41]. 
Clinical reports on the prevalence of HADL are highly variable. The percentage 
of patients presenting with symptoms associated with lipodystrophy and dyslipidemia 
range from 20% to as high as 80% [42-44]. The lack of a unifying definition of HADL 
combined with interpretational differences in the significance of changes in syndrome 
markers is a likely reason for variability in the incidence of HADL in patient populations 
[45]. Despite these statistical differences, it is certain that long-term HIV survivors will 
face additional health risks and quality of life issues associated with HAART.  
 
1.1.3 Risk Factors Associated with HADL 
The exact mechanisms that causes HADL is unknown, but certain factors have 
been associated with an increased risk of developing HADL. PIs have the strongest 
clinical link to HADL but other factors such as duration of infection and treatment, use of 
NRTIs, age and gender may contribute to the overall risk of developing HADL [46].  
PIs account for the majority of metabolic symptoms of HADL. Many clinical 
studies have been conducted and have provided strong statistical evidence supporting a 
direct link between HAART containing PIs and HADL [47-50]. Data are sparse for PI 
only effects since the majority of HIV patients are on HAART where assignment of side 
effects to specific drugs is difficult. Studies where patients receiving PIs are switched to a 
non-PI therapy have shown marked improvement in HADL symptoms especially 
improvements in cholesterol and triglyceride levels with modest reversal of body fat 
remodeling [51-53]. Whereas most PIs have been found to induce dyslipidemia in HIV-
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positive individuals, short course indinavir treatment had no effect on plasma lipid levels 
in HIV-negative subjects, and caused only mild hyperlipidemia in HIV-positive 
individuals [54]. In contrast, both HIV-positive and HIV-negative subjects treated with 
ritonavir displayed a robust increase in plasma cholesterol and triglyceride after short 
exposure time [54, 55]. There is little evidence for differential effects of specific PIs 
regarding the incidence of HADL, with the exception of ritonavir whose association with 
development of hypertriglyceridemia and hypercholesterolemia is stronger than for other 
PIs [56]. Atazanavir, a PI approved in 2003 for treatment of HIV infection, has 
demonstrated comparable antiviral activity to current PIs and has been shown to improve 
lipid profiles when substituted for other PIs in HAART [57]. Atazanavir may very well 
serve as the frame work for development of new PIs with decreased side effects, 
however, data concerning long-term use and the potential for development of HADL is 
still being collected [58].  
The length of infection has been shown to have a negative impact on lipid 
profiles. Lipid abnormalities have been observed in HIV patients prior to implementation 
of HAART and in HAART-naïve patients. Lipid abnormalities resulting from HIV 
infection alone are characterized by a decrease in both LDL and HDL levels and an 
increase in TGs [59]. After patients begin receiving HAART, the lipid profile is 
transformed into a proarthrogenic profile by boosting TGs and LDL levels while leaving 
HDL levels unchanged [59, 60]. 
Increased risk of developing HADL is also associated with the age and gender of 
a patient [61]. Older individuals within the patient population tend to have higher 
cholesterol levels than younger patients at the beginning of treatment, providing a higher 
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cholesterol baseline for HAART treatment to build on. Male gender is also a risk factor 
for developing HADL due to a higher baseline of cholesterol and triglyceride levels in 
this patient population. However, studies have shown that women are more prone to 
adipose tissue alterations than male patients [62, 63].  
Data suggest that use of NRTIs may be a risk factor for developing lipodystrophy 
associated with HADL. Peripheral loss and visceral accumulation of fat have been 
reported in PI-naïve patients treated with NRTIs alone [64, 65]. This redistribution of fat 
is often indistinguishable from those observed in PI-induced lipodystrophy [66]. Data are 
inconsistent concerning the effects of NRTIs on glucose tolerance and lipid profiles. In 
fact, patients with NRTI-associated body fat redistribution usually have normal or lower 
than normal lipid, glucose and insulin levels when compared to PI-related HADL patients. 
[64, 66].   
NRTIs are effective as anti-HIV therapies due to their inhibition of HIV reverse 
transcriptase. The proposed pathway by which NRTIs cause lipodystrophy is thought to 
occur through the off-target inhibition of mitochondrial DNA polymerase gamma [6]. 
Interference in replication of mitochondrial DNA results in overall mitochondrial 
toxicity, mitochondrial DNA mutations and a reduction in mitochondrial function 
pertaining to β-oxidation of fatty acids and cytochrome c oxidation [6, 67]. Similar 
symptoms to HADL lipodystrophy have been reported in patients with the genetic 
disorder familial multiple symmetric lipomatosis (MSL) [68]. Familial MSL is generally 
caused by point mutations in mitochondrial DNA resulting in mitochondrial dysfunction 
and is characterized by marked accumulation of nonencapsulated adipose tissue around 
the neck (horse collar and buffalo hump), shoulders, and upper torso regions [69, 70]. 
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Current evidence suggests that therapies containing NRTIs may be an aggravating factor 
for development of HADL by providing an additional risk factor for developing 
lipodystrophy but lack the metabolic effects observed in therapies containing PIs. 
 
1.1.4 Cellular Mechanisms 
The exact mechanism by which PIs initiate metabolic disturbances leading to 
HADL remains elusive. From the time HADL was first observed in the clinic, researchers 
have been focused on uncovering the underlying mechanism in the hope of minimizing 
side effects of current HIV therapies. Clinical observations of altered serum lipid and 
glucose levels and peripheral lipoatrophy in HADL patients indicate that PIs are likely 
interfering with effectors of lipid and glucose homeostasis. Some of the metabolic 
processes shown to be impacted by HIV PIs in vitro are inhibition of the glucose 
transporter-4 (GLUT4), inhibition of apolipoprotein B (ApoB) degradation, inhibition of 
preadipocyte differentiation and dysregulation of sterol regulatory element binding 
proteins (SREBPs) [71-73].  
Entry of glucose into peripheral tissues is facilitated by GLUT4. After feeding, 
glucose levels rise, triggering release of insulin from the pancreas. Circulating insulin 
interacts with cell surface insulin receptors (IR), resulting in a signaling cascade 
involving various key signaling proteins including insulin receptor substrate 1 (IRS1), 
phosphatidylinositol 3-Kinase (PI3K) and Akt (Figure 2) [74]. Activated Akt moves from 
the cell surface back into the cytoplasm where it triggers the movement of GLUT4 to the 
cell surface. The mechanism through which Akt initiates the movement of GLUT4 is 
thought to occur through subsequent interactions with unknown cellular components 
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[75]. GLUT4 is incorporated into the membrane through the interaction of the vesicle-
associated membrane protein (VAMP), associated with GLUT4 containing lipid vesicles, 
and Syntaxin on the membrane surface. Once positioned within the cellular membrane, 
GLUT4 begins active transport of glucose into the cell.  
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Figure 2. Model of Insulin Signaling and Transport of GLUT4 to the Cell Membrane. Insulin initiates 
uptake of glucose by triggering a cascade of kinase activity resulting in movement of GLUT4 to the cell 
surface. After feeding, insulin levels rise and insulin interacts with cell surface insulin receptors. This 
interaction activates the tyrosine kinase activity of the cytoplasmic portion of the insulin receptor which 
results in the phosphorylation of IRS. Phosphorylated IRS is then able to bind PI3K. PI3K phosphorylates 
membrane phospholipids allowing the binding of both PDK and Akt. When PDK and Akt are in close 
prosimity, PDK is able to phosphorylate Akt. Akt moves away from the cell surface and interacts with 
cytoplasmic substrates. Interaction with an, as of yet, unidentified substrate causes the movement of 
GLUT4-containing vesicles to the cell surface. The vesicles are integrated into the plasma membrane 
through the interaction of Syntaxin and VAMP. Once embedded in the membrane GLUT4 actively 
transports glucose into the cell where it can be used for energy or stored as glycogen and fatty acids. HIV 
PIs have been shown to interact directly with GLUT4 and prevent uptake of glucose. 
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 PIs have been shown to act as reversible noncompetitive inhibitors of GLUT4 
with binding affinities in the low micromolar range, well within estimated serum 
concentrations of most PIs [76, 77]. PIs also inhibit glucose transport by other GLUT 
isoforms although to a lesser extent than that observed with GLUT4. Indinavir is the only 
PI to show specificity in inhibition of GLUT4 and has been used to investigate the role of 
different GLUT isoforms in glucose uptake in tissues [78]. PI inhibition of peripheral 
uptake of glucose from circulation can result in hyperglycemia and insulin resistance, 
contributing significantly to alterations in glucose homeostasis. 
Lipids, phospholipids and cholesterol esters are insoluble in plasma. These lipids 
combine with apoproteins to form lipoproteins for transport to and from the periphery. 
Apoproteins are important not only in maintaining the structural integrity of lipoproteins 
and thereby facilitating the solubilization of lipids, but they also play an important role in 
lipoprotein receptor recognition and regulation of certain enzymes in lipoprotein 
metabolism. Apolipoprotein B is the apoprotein associated with chylomicron, LDL, IDL 
and VLDL lipoprotein particles. An increased ratio of ApoB/ApoA-I containing 
lipoproteins is predictive of CAD risk [79]. 
Use of PIs has been shown to increase serum levels and resident time of ApoB 
containing lipoproteins like VLDL and IDL, independent of other risk factors. Whether 
the overall increase is due to an actual increase in hepatic lipoprotein production [80-82] 
or decrease clearance of ApoB lipoproteins through reduced expression of the LDL 
receptor [83, 84] or a combination of both is uncertain. A recent publication indicates that 
reduced levels of adiponectin, through loss of peripheral fat, directly correlates with 
VLDL and LDL clearance rates in treated and non-treated HIV patients [85]. Reduced 
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adiponectin levels may lead to reduced clearance of ApoB containing lipoproteins 
through transcriptional repression of lipases. Indicating that increased ApoB lipoproteins 
levels may be due in part to changes in peripheral and visceral storage of fat and 
concomitant change in adipokine signaling. Inhibitory effects of PIs on the proteasomal 
degradation of ApoB may be another contributing factor to the elevated levels of ApoB 
lipoprotein [80, 86]. The amount of ApoB secreted from the liver is regulated primarily 
by the rate of ALLN (N-acetyl-leucyl-leucyl-norleucinal)-sensitive proteasomal 
degradation of newly synthesized ApoB. PIs prevent the degradation of ApoB and lipid 
biosynthesis resulting in cellular accumulation of ApoB. The ApoB stock pile remains in 
the liver until lipid availability increases, as occurs in peripheral insulin resistance. 
Prolonged residence time of ApoB-containing lipoproteins allows for extensive exchange 
of TGs for cholesterol esters with HDL, increasing clearance rates of HDL and formation 
of oxLDL, contributing to CAD risk. 
Transcription of genes involved in the synthesis of fatty acids, triglycerides, and 
cholesterol are in part controlled by the sterol regulatory element-binding proteins 
(SREBPs) [87]. SREBP-1 and -2 are synthesized as precursor proteins bound to the ER 
membrane and nuclear envelope. In order to enter the nucleus and activate gene 
transcription, SREBP must be released from the membrane by the SREBP cleavage–
activating protein (SCAP). When cells become depleted in cholesterol, SCAP escorts 
SREBP to two proteases that are responsible for cleavage. Processing by site protease-1 
and-2, results in the transcriptionally active SREBPs. The SREBP can be classified based 
on their transcriptional activity on lipid pathways. SREBP-1a is a general activator of 
gene expression for all SREBP target genes whereas, SREBP-1c and SREBP-2 are more 
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restricted to transcriptional activation of gene sets involved in fatty acid and cholesterol 
synthesis, respectively.  
Experiments in mice show that exposure to PIs, especially ritonavir, induces 
accumulation of SREBP-1 and SREBP-2 in the nucleus of both adipose and liver tissues 
[88]. However, mRNA levels of SREBPs were unchanged when compared to control 
animals suggesting that increased levels of nuclear SREBPs were due to mechanisms 
other than increased transcription of the SREBP gene. The turn over of transcriptionally 
active SREBPs is also controlled by ALLN (N-acetyl-leucyl-leucyl-norleucinal)-sensitive 
proteasome degradation involving calpain-like enzymes and the 20S proteasome  [89]. 
PIs have been shown to interfere with ALLN-sensitive proteasome processing of antigens 
in T cells and the presecretory degradation of ApoB discussed previously [86, 90]. It is 
through the inhibition of proteasome degradation of nuclear SREBPs that accumulation 
of active SREBPs is believed to occur [88]. Constitutively active SREBPs would result in 
increased unregulated transcription of crucial enzymes of de novo fatty acid and 
cholesterol synthesis such as fatty acid synthase (FAS), acyl CoA carboxylase (ACC) and 
HMG CoA synthase [87]. In fact, transgenic mice over-expressing active SREBP-1 
display similar symptoms as those found in HADL including dyslipidemia, insulin 
resistance and fat remodeling [91]. 
Despite the progress made towards understanding the off-target cellular 
interactions of PIs, the redundant nature and complexity of metabolic pathways make it 
difficult to identify clinically relevant cellular mechanisms in the pathogenesis of HADL. 
The high dose of PIs required to achieve therapeutic effects further confound the problem 
by increasing the likelihood of multiple off-target interactions [92, 93]. It is apparent that 
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HADL likely results from the disruption of multiple pathways involved in energy 
homeostasis in various tissue types for full manifestation of HADL.  
 
1.1.5 HADL-Like Diseases 
Metabolic diseases reminiscent of HADL have been observed outside of the 
context of HIV infection and HAART. In fact, the first cases of HADL were initially 
described as a ‘pseudo-Cushing’s’ syndrome due to the similarity in symptoms observed, 
specifically, peripheral lipoatrophy, truncal obesity and abnormal fat deposit on the upper 
back and neck [26]. Cushing's syndrome is a disease caused by the prolonged exposure of 
the body’s tissues to high levels of circulating cortisol [94]. The syndrome is used to 
describe effects of cortisol excess through either hypothalamic-pituitary-adrenal axis 
(HPA axis) dysfunction or from excessive use of cortisol or other glucocorticoids. 
Genetic forms of Cushing’s syndrome are rare and most cases occur through the use of 
steroids for treating chronic conditions such as asthma. Cushing’s is mainly a 
lipodystrophy associated syndrome but is also associated with hypertension, insulin 
resistance and hyperglycemia. Despite the similarities, patients with HADL do not have 
elevated levels of circulating cortisol characteristic of Cushing’s syndrome [26]. 
Interestingly, Syndrome X (also known as the metabolic syndrome), described as 
Cushing’s syndrome of adipose tissue, also lacks elevated levels of cortisol associated 
with Cushing’s syndrome [95].  
Syndrome X is used to describe a cluster of metabolic dysfunctions linked to the 
dramatic rise of CAD and diabetes in industrialized nations [95]. Metabolic syndrome is 
associated with increased visceral obesity, dyslipidemia and insulin resistance without the 
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associated peripheral lipoatrophy observed in HADL. The foundation of metabolic 
syndrome resides in diet-induced obesity and the concomitant accumulation of visceral 
adipose. The visceral adipose of obese people has been found to have increased activity 
of the 11-beta-hydroxysteroid dehydrogenase type 1 (11βHSD1) enzyme when compared 
to the activity in adipose of non-obese individuals.  
11βHSDs are glucocorticoid (GC) metabolizing enzymes that modulate the 
interconversion of active (cortisol, corticosterone) and inactive (cortisone, 
dehydroxycorticosterone) GCs in tissues [96]. The primary role of GCs is to mobilize 
stored fuel sources through gluconeogenesis, lipolysis and mobilization of amino acids 
[97]. The role of 11βHDs is to control access of GCs to the glucocorticoid (GR) and 
mineralocorticoid receptors (MR) by either dampening or amplifying the concentration of 
GCs above circulating levels in specific tissues [96, 98]. In contrast to the effects of 
Cushing’s disease, increased 11βHSD1 activity in adipose tissue does not result in 
increased circulating levels of cortisol, in fact, serum levels of GCs are normal [99, 100]. 
The isolated activity of 11βHSD1 directly impacts the composition of serum lipids and 
peripheral insulin sensitivity through the release of FFAs, adipokines and 
proinflammatory cytokines from adipocytes into circulation [101].  
Research has shown that the adipose tissue of patients with HADL have unusually 
high levels of 11βHSD1 mRNA, indicating that there is a potential for increased 
11βHSD1 activity at these sites [102, 103]. Due to the pandemic nature of the metabolic 
Syndrome, much interest surrounds the development of therapeutics aimed at the 
inhibition of 11βHSD1. It is possible that advancements in the treatment of the Metabolic 
syndrome may also aid in the management and understanding of HADL. 
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HADL is classified as an acquired lipodystrophy. Lipodystrophies are disorders of 
adipose tissue characterized by selective loss of fat from various parts of the body [104]. 
There are several different types of lipodystrophies and can be either inherited or 
acquired, as in the case of HADL and metabolic syndrome. Inherited lipodystrophies 
arise from mutations in genes essential to the function and maintenance of adipose tissue. 
In the context of HADL and similarity in clinical manifestation, the most relevant 
inherited lipodystrophies are the type 2 and 3 familial partial lipodystrophies (FPLD). 
FPLD is characterized by fat loss from limbs and the gluteal region at puberty, while 
central, facial and visceral fat remain unaltered. FPLD2 results from mutations in the 
nuclear lamin A/C gene, while FPLD3 is linked to a variety of loss of function mutations 
in PPARγ. The extent of lipodystrophy and metabolic disturbances differ between FPLD2 
and FPLD3. Patients with FPLD2 tend to have a more significant reduction in adipose 
but less metabolic dysfunction when compare to patients with FPLD3. Early 
investigations into the underlying mechanism of HADL stemmed from the observation 
that the severe metabolic effects in patients with FPLD3 were similar to HADL patients 
and that the symptoms of HADL could be due to PI interference of PPARγ activation 
[18].  
 
1.1.6 HADL and PPARγ 
Conflicting results have been reported on the effects of PIs on PPARγ function.  
Saquinavir and indinavir have been shown to inhibit differentiation of preadipocytes in 
culture, a function firmly attributed to functional PPARγ. However, levels of aP2 
expression, a known PPARγ target gene, were found to be unaffected [105, 106]. Lenhard 
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et al. also reported decreased adipogensis, lipogenesis and increased lipolysis upon 
exposure of adipocytes to saquinavir, ritonavir and nelfinavir but with an associated 
decrease in mRNA levels of adipocyte markers, aP2 and LPL [107]. In contrast, similar 
experiments performed by Ragnathan and Kern showed decreased activity of LPL in 
adipocytes without a decrease in mRNA levels upon exposure to saquinavir suggesting 
PIs may act through alterations in post-translational processing rather than transcription 
[108]. PI effects on lipolysis, lipogenesis and expression of aP2 and LPL are opposite to 
effects observed for PPARγ agonists in cultured adipocytes. Further, treatment of HADL  
patients with rosiglitazone and metformin, known agonists of PPARγ, provides at least 
moderate improvements in both insulin resistance and fat distribution [109]. Despite 
circumstantial evidence suggesting involvement of PPARγ in HADL, direct interaction 
between PIs and PPARγ have yet to be established.  
With the exception of PPARγ, nuclear receptors have been largely overlooked as 
potential targets of PIs in the development of HADL.  The severity of metabolic changes 
observed in patients with HADL suggests that a whole body disruption of energy 
regulation is occurring. Maintenance of energy homeostasis is achieved through the 
coordinated control of diverse cellular mechanisms. The activity and availability of key 
enzymes and transporters within a pathway are modulated by the fine tuning of activation 
states, allosteric control of substrate binding and gene expression levels in response to 
nutritional status. Gene expression is controlled by nuclear receptors that are sensitive to 
fluctuations in concentrations of endogenous and exogenous biological modulators such 
as drugs, hormones, steroids and metabolic intermediates. Nuclear receptors serve as 
metabolic sensors whose activation, or suppression, has the potential for long lasting 
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global effects on pathways of energy utilization. The role of nuclear receptors as major 
transcriptional regulators directly affecting the abundance of target genes in multiple 
metabolic pathways and the potential for PI-mediated desensitization to intrinsic ligands, 
make them ideal candidates in the pathology of HADL.  
 
1.2 Nuclear Receptors 
1.2.1 Structure and Function 
Gene activation is highly regulated to ensure that appropriate genes are turned on 
or off according to environmental, developmental and cell cycle controls. The core 
transcriptional enzyme, RNA polymerase II (Pol II), requires several general transcription 
factors to perform functions related to DNA unwinding as well as initiation and 
elongation of transcripts [110]. Pol II and the general transcription factors form what is 
known as the basal transcriptional machinery. The basal transcriptional complex is 
sufficient to maintain low levels of cellular gene transcription. However, high levels of 
regulated, gene-specific transcription require the additional action of ligand-activated 
transcription factors bound to DNA enhancer element in the promoter region of 
responsive genes. These ligand-activated transcription factors or nuclear receptors mark a 
specific gene or a subset of genes for increased transcription by the basal machinery to 
enhance the transcriptional response to cellular signals [111].  
Nuclear receptors are activated primarily through the binding of small, lipophilic 
ligands that include hormones and endogenous metabolites such as fatty acids, bile acids, 
oxysterols, and xenobiotics [112]. The activation state of nuclear receptors can also be 
influenced by other mechanisms including, phosphorylation by cellular kinases in cell 
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signaling pathways and protein-protein interactions through contacts with other 
transcription factors [113]. Most members of the nuclear receptor superfamily were 
originally identified by surveying the genome for stretches of DNA sequences 
homologous to the classic steroid receptors, GR and estrogen receptor (ER) [114]. The 
newly discovered receptors were called ‘orphan’ receptors because, at the time, little was 
known about their function or endogenous ligands. The discovery of these receptors was 
based on the observation that nuclear receptors are constructed of four independent but 
interacting functional domains and that the sequence of these domains are conserved 
across the receptor family [115]. The four functional domains are the modulator domain, 
DNA binding domain (DBD), hinge region and ligand binding domain (LBD) (Figure 3). 
The regions of greatest sequence homology among nuclear receptors reside in the LBD 
and DBD with the hinge and modulator domain having the least similarity. The 
nomenclature of the nuclear receptor family is based on sequence identity within the 
LBD and DBD [116]. Receptors within the same group must share at least 80-90% 
identity within the DBD and at least 40-80% identity within the LBD. The human nuclear 
receptor superfamily contains a total of 48 nuclear receptors divided into 7 subfamilies 
and 26 groups.  
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Figure 3. Nuclear Receptor Structural and Functional Domains. The A/B domain, the most variable 
domain among receptor groups, contains a ligand-independent activation function (AF-1) and coactivator 
protein binding sites. The C domain is highly conserved and contains zinc finger motifs essential for 
response element binding. The D domain or hinge region provides flexibility to the nuclear receptor 
structure as well as binding sites for corepressors. Ligand-dependent transactivation depends on the 
carboxy-terminal E domains which undergo conformational change upon binding of ligand, allowing for 
proper positioning of the AF-2 and recruitment of coactivator proteins. The exact function of the F domain 
is unknown and is present only in certain nuclear receptor groups. 
 
 
 
The DBD, also known as the C domain, is highly conserved in sequence across 
the receptor family due to its function in DNA binding. The function of the DBD is 
recognition and binding of activated receptors to target gene response element sequences 
[117].  DNA response elements (RE) are comprised of two hexameric nucleotide 
sequences known as half sites located in the promoter region of nuclear receptor 
responsive genes [115]. The sequence, arrangement and spacing of the half sites define 
the responsiveness of a gene to various nuclear receptors. In general, steroid receptors 
preferentially recognize AGAACA half sites and bind as homodimers. Receptors that 
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form a heterodimer pair with RXR typically recognizes AGGTCA as their half site with 
variable nucleotide spacing between the two half sites. Together with the nucleotide 
spacing of half sites, the arrangement as either direct, inverted or everted repeats convey 
receptor specificity. The DBD is GC-rich and contains two zinc finger motifs with a 
carboxy-terminal extension containing T and A boxes critical for monomeric DNA 
binding of RE half-sites [112, 117]. The first zinc finger contains amino acid sequences, 
known as the P box, that are essential for recognition of DNA RE sequences of target 
genes. The second zinc finger contains the D box which provides an interface for 
dimerization with the DBD of either a homodimer or heterodimer partner occupying the 
other half site of the RE. 
The LBD, also known as the E/F domain, is a multifunctional domain with 
sequences critical for ligand binding, ligand-dependent transactivation function (AF-2), 
receptor dimerization, nuclear localization and the binding of coactivators and heat shock 
proteins [115, 118]. All nuclear receptor LBDs are comprised of 12 α-helices arranged to 
form three separate helical sheets that form a hydrophobic pocket suitable for binding of 
lipophilic ligands [118]. The steroid receptor group members, such as GR and MR, 
require the binding of heat shock proteins for proper orientation of LBD helices and 
arrangement of the hydrophobic pocket. Binding of ligand triggers rearrangement of the 
LBD helices, releasing heat shock proteins and corepressors. The carboxy-terminal helix 
12, containing the AF-2, is positioned across the LBD pocket exposing sequences 
required for coactivator protein interactions rendering the nuclear receptor 
transcriptionally active. 
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The hinge region, also known as the D domain, is a stretch of sequence between 
the DBD and LBD that is variable in both length and sequence between receptor groups 
[115]. The hinge region contains binding sequences for corepressors, essential for 
transcriptional silencing.  The hinge region also provides flexibility to the receptor 
domains for proper orientation for both RE binding and dimmer formation.  
The amino-terminal modulator domain, also known as the A/B domain, contains 
amino acid sequences conveying ligand-independent activation function (AF-1) [115]. 
Truncated expression of receptors, lacking the LBD portion of the receptor sequence, 
were found to retain functional activation despite the inability to bind ligand. This region 
also contains sites targeted for phosphorylation by different signaling pathways [119]. 
Effects on activation due to phosphorylation are receptor-specific and can result in either 
enhanced or diminished receptor activation. Binding sites for coactivator proteins, 
essential cofactors for gene transcription, are highly concentrated in the LBD domain and 
are only accessible upon ligand binding. Coactivator binding sites have also been 
identified in the modulator region, indicating that transcriptional events mediated through 
unliganded receptor activation are completely independent of LBD function. Although 
AF-1 and AF-2 are capable of regulating transcription alone, full transcriptional 
activation by AF-2 requires functional interactions between the two regions [118, 120]. 
The interaction facilitates sustained receptor activation and robust gene transcription 
through stabilization of helix 12 preventing premature dissociation of ligand and mutual 
binding of coactivators. Although nuclear receptors, in general, share significant 
homology in both primary amino acid sequence and tertiary structure, the modulator 
domain shows little or no sequence homology between the different families of receptor 
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[117]. In fact, the modulator domain is virtually nonexistent in some members of the 
nonsteroidal receptor group, indicating that these receptors are activated primarily 
through ligand binding. The nuclear receptor superfamily can be divided into groups 
based on the specific mechanisms involved in their activation [112, 115]. Type 1 nuclear 
receptors encompass the steroid hormone binding class of receptors consisting of GR, 
MR, androgen receptor (AR), progesterone receptor (PR) and ER. While in an 
unliganded state, these receptors reside in the cytoplasm bound by heat shock proteins 
(HSPs), specifically HSP90 [121]. Steroid hormones diffuse freely across the plasma 
membrane and bind to the receptor facilitating the release of HSPs, allowing 
homodimerization and translocation of the receptor to the nucleus. The remaining 
members of the nuclear receptor superfamily are classified as type 2 receptors and serve 
as receptors for nonsteroidal hormones and intermediates of metabolism such as fatty 
acids, bile acids and oxysterols. Unlike the type 1 receptors, Type 2 receptors do not 
require association with HSPs and move freely between cytoplasm and the nucleus [122]. 
In the nucleus, many of these receptors are found to be transiently associated with 
chromatin, implying that type 2 receptors interact with target gene REs in an inactivated 
state. Many of the type 2 receptors actively repress basal transcription by recruiting 
corepressors which are released in the presence of ligand (Figure 4). The majority of type 
2 receptors exist as heterodimers with RXR although some receptors from this group, 
such as NGFI-B and HNF-4, function as monomers and homodimers, respectively [115]. 
Despite the differences between the type 1 and 2 receptors concerning cellular 
localization, dimerization and RE binding, both share similar mechanisms in target gene 
transcription.  
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Figure 4. Model of Type 2 Nuclear Receptor Activation. Type 2 nuclear receptors form heterodimers 
with RXRα. These heterodimers are capable of binding DNA in an unliganded state. Bound to target gene 
response elements, type 2 receptors can actively repress basal transcription through the binding of 
corepressors. Binding of ligand triggers conformational changes resulting in release of corepressors and 
recruitment of coactivators. The coactivator complex removes repressive chromatin structures through the 
acetylation and methylation of histones providing access to promoter regions for RNA polymerase II and 
the general transcription factors (GTFs). 
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Once activated and bound to target gene REs, nuclear receptors must recruit and 
bind coactivator proteins in order to increase gene transcription. Initially, coactivator 
proteins were considered silent obligate participants in nuclear receptor transcriptional 
events, providing a bridge between DNA binding transcription factors and the general 
transcription machinery, with little influence over the transcriptional event itself [123]. 
Advancements in the field have shown that the function of coactivator proteins in 
controlling gene transcription is much more complex.  
To date, ~200 members of the coactivator protein family have been identified 
with 50-70 having been characterized as coactivators exclusive to nuclear receptors 
[124]. Unlike nuclear receptors, coactivators are structurally and functionally diverse. 
Not only do coactivators serve as adapters between the receptor and general 
transcriptional machinery, but also perform enzymatic activities essential to transcription. 
The primary function of coactivators is the remodeling of chromatin through the 
modification of histones [125]. Acetylation and methylation of histones by coactivators 
removes repressive chromatin structures providing access of transcription factors to 
enhancer and promoter regions of DNA targeted by nuclear receptors. In addition to 
chromatin remodeling, coactivators also influence the termination of transcriptional 
events through ubiquitin ligase activities and splicing decisions of the resulting RNA 
transcripts. 
Recruitment of coactivators results in a multifunctional coactivator complex. The 
assembly and content of the coactivator complex is influenced by many factors including 
cellular coactivator abundance and affinity as well as the type of RE and ligand bound by 
the nuclear receptor. Assembly of the complex is initiated through the binding of a core 
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coactivator which interacts directly with the nuclear receptor through its LXXL motif 
[126]. Coactivators contain several LXXL motifs with flanking sequences conveying 
affinity for certain receptors thus enabling coactivators the ability to bind to different 
combinations of nuclear receptors [127]. The LXXL flanking sequences are subject to 
posttranslational modifications which influence the binding affinity of coactivators to 
nuclear receptors and other coactivators [128]. These postranscriptional modifications are 
mainly phosphorylation events mediated by kinases in cell signaling pathways. 
Phosphorylation at the LXXL motif and other regions within the coactivator as well as 
enzymatic actions by other coactivators provides an opportunity for the fine tuning of 
transcriptional events outside of the context of nuclear receptor activation. The content of 
the coactivator complex is also dictated, in part, by cellular abundance. Coactivators, like 
nuclear receptors, have tissue specific expression patterns that change in response to the 
cellular environment [129, 130]. Peroxisome proliferator-activated receptor gamma 
coactivator-1 alpha (PGC-1α) has been found to be expressed at higher levels in muscle 
in response to strenuous exercise [131]. Altered expression levels of coactivators have 
also been found during embryonic development and in certain cancers, such as prostate 
and breast cancer [132-135].  Differential expression of coactivators has the potential to 
influence the content of the coactivator complex and the resulting transcriptional 
activation of gene subsets by an activated nuclear receptor [136, 137].  
Coactivator recruitment is also influenced by the type of ligand bound by the 
nuclear receptor as demonstrated by the variability of gene responses to different ligands. 
Binding of tamoxifen instead of the natural ligand, estrogen, to the estrogen receptor 
alpha (ERα) changes the binding preference of ERα to specific response elements and 
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alters coactivator preference [138]. Diversity in DNA sequence among target gene REs 
can cause subtle differences in binding of the DBD of a receptor which in turn influence 
the conformation of the entire receptor. Differences in RE sequence can change the 
conformation of the LBD resulting in alterations in both ligand affinity and coactivator 
preference.  
 
1.2.2. Nuclear Receptors of Metabolism 
1.2.2.1 Peroxisome Proliferator Activated Receptors (PPARs) 
PPARs, and the potential benefit of PPAR activating drugs, have been the focus 
of intensive research in the treatment of obesity, diabetes and the metabolic syndrome 
[139, 140]. Metabolic syndrome is characterized by visceral fat accumulation, 
hyperlipidemia, elevated triglycerides, elevated blood pressure, and hyperglycemia [141], 
symptoms similar to those found in HADL and FDLP3, to which PPARγ mutations have 
already been linked (1.1.5). The PPAR family of nuclear receptors is comprised of three 
isotypes, α, γ and δ. PPARs are activated by a wide range of endogenous and dietary fatty 
acids and their derivatives such as prostaglandins and leukotriens [142-144]. PPARs 
regulate lipid, cholesterol and glucose homeostasis through coordination of gene 
transcription effects in liver, muscle and adipose tissue. While the PPARs share common 
ligands, the differential tissue expression pattern, distinct coactivator recruitment 
preference and variable affinity for ligands results in isotype-specific effects on target 
gene expression [145, 146].  
The primary role of PPARα is the regulation of β-oxidation of fatty acids [142]. 
PPARα is highly expressed in tissues with high rates of fatty acid catabolism such as the 
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liver, muscle, kidney and intestine. During fasting, fatty acids are released from 
adipocytes and transported to the liver. PPARα activation by fatty acids increases 
transcript levels of genes such as acyl CoA oxidase (ACO) resulting in the increased 
production of ketone bodies for energy utilization by peripheral tissues [147]. Fatty acid 
β-oxidation also occurs in skeletal muscle but regulation at this site is not exclusive to 
PPARα, highlighting the overlapping control of such vital processes. PPARα also 
enhances uptake and transport of circulating fatty acids through modulation of target 
genes such as apolipoprotein A (ApoA), fatty acid binding proteins (FABP) and LPL. 
Activation of PPARα by dietary polyunsaturated fatty acids (PUFAs) and the fibrate 
class of hyperlipidemic drugs has been shown to have beneficial effects on circulating 
triglyceride levels and plasma lipid profiles [142]. In addition to its role in lipid 
metabolism, PPARα also effects gluconeogenesis in the liver and pancreatic islets by 
promoting the use of pyruvate in gluconeogenesis rather than fatty acid synthesis through 
upregulation of pyruvate dehydrogenase kinase 4 (PDK4). In general, PPARα serves to 
direct lipids to the liver while PPARγ activates storage of lipids in peripheral tissues 
working in concert to maintain balance between energy storage and utilization. 
PPARγ is a major regulator of both adipocyte differentiation and the subsequent 
uptake and storage of lipids in the mature adipocyte. Activation of PPARγ in the 
preadipocyte promotes cell cycle arrest through the induction of cell cycle inhibitors such 
as p18 and p21, inhibitors of cyclin-dependent kinase (CDK), along with repression of 
cyclins [148]. During differentiation, expression of genes essential for transformation of 
the preadipocyte to a mature adipocyte is increased. Adipose differentiation related 
protein (ADRP), a well known target gene of PPARγ, is upregulated during 
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differentiation and is essential to maintenance of lipid droplet structure in adipocytes 
[149]. Loading of adipocytes with lipid is achieved through the upregulation of PPARγ 
genes involved in the removal of fatty acids from circulating lipoproteins, such as LPL, 
and transport of these fatty acids into the adipocyte through fatty acid transport protein 
(FATP) [147, 150].  
PPARγ is also a major regulator of insulin sensitivity and it is this specific 
function that is the target of therapies directed towards activation of PPARγ. 
Thiazolidinones or TZDs, such as rosiglitazone and pioglitazone, are marketed 
PPARγ agonists that are highly effective in the treatment of type 2 diabetes [151]. The 
insulin sensitizing effects of TZDs are thought to be a result of PPARγ activation in 
adipose and the beneficial shift of fatty acid storage to adipose rather than muscle and 
liver, minimizing insulin resistance associated with fatty acid storage in non-adipose 
tissues. PPARγ activation also results in increased release of adipokines, such as 
adiponectin, from adipose tissue and may contribute to the insulin sensitivity of TZDs 
[152]. In addition to expression in adipose, PPARγ is also expressed in tissues essential to 
glucose homeostasis such as, the liver, pancreas and muscle, but at levels much lower 
than those observed in adipose tissue. The role of PPARγ in these tissues is poorly 
understood but has raised questions concerning the possibility of PPARγ playing a direct 
role in glucose uptake, storage and signaling. PPARγ REs have been located in the 
glucose transporter 2 (GLUT2) and liver glucokinase (GK) genes, two genes critical to 
postprandial glucose uptake and signaling in the liver and pancreas [153]. Consistent with 
these findings, both GLUT2 and L-GK transcript levels increase in the presence of 
PPARγ agonists in cultured cells [154, 155]. The products of these genes are essential for 
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the facilitated transport and retention of glucose, allowing efficient glucose stimulated 
insulin secretion (GSIS) in pancreatic beta cells and storage of glucose as glycogen in the 
liver. It is possible that the positive effects of TZD through activation of PPARγ may 
have a direct effect on insulin secretion in addition to improving peripheral insulin 
sensitivity. 
PPARδ, the least characterized of the PPAR family members, is ubiquitously 
expressed and has been implicated in fatty acid transport and oxidation, as well as, 
inflammatory responses, wound healing and maintenance of adipocytes [156]. The 
development of specific, high affinity PPARδ agonists have provided insight into the 
effect of PPARδ on serum lipid composition and fat deposits in animal models of obesity 
and diabetes [157]. PPARδ activation has been shown to increase HDL levels by as much 
as 78% and decrease adipose tissue fat deposits, TGs and LDL particles [158, 159]. The 
improved serum lipid profile through activation of PPARδ is presumed to result from an 
increase in expression levels of the reverse cholesterol transporter, ATP binding cassette 
A1 (ABCA1). These positive effects of PPARδ specific agonists suggest PPARδ may be 
a suitable target for the treatment of hyperlipidemia. 
Skeletal muscle expression of PPARδ has been found to be ~10-50 fold higher 
than either of the other PPAR family members, making skeletal muscle the primary tissue 
for PPARδ-specific effects [160]. PPARδ in skeletal muscle is associated with oxidative 
slow-twitch fibers where it regulates the expression of genes involved in fatty acid 
transport, oxidation and glucose uptake. Activation of PPARδ has been shown to increase 
the expression of myoglobin and tropinin 1 slow, which influence the change of muscle 
fiber type from glycolitic to oxidative [161, 162].  High proportions of oxidative slow-
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twitch fibers in muscle have been demonstrated to provide protection against obesity, 
diabetes and contribute to an overall increase in muscular endurance [161].  
 
1.2.2.2 Farsenoid X Receptor and Liver X Receptor 
Farsenoid X receptor (FXR) and liver X receptor alpha (LXRα) play a pivotal 
role in total body cholesterol homeostasis. LXR activation is triggered by increased levels 
of oxysterols, which increase in proportion to cellular cholesterol content [163, 164]. 
LXR facilitates the processing and storage of cholesterol by upregulating cyp7A1 
expression, the rate limiting enzyme in the conversion of cholesterol to bile acids. LXR 
responds to high cholesterol levels by increasing fatty acid synthesis to increase the 
formation of cholesterol esters, rendering the excess cholesterol pool biologically inactive 
[165].  
 LXR also facilitates efflux of cholesterol from the periphery, including 
macrophages, through the increased expression of ABC transporters [166]. Induction of 
ABC transporters increases the transfer of cholesterol and phospholipids to ApoA1 
containing lipoproteins and may contribute to the increased levels of c-HDL seen with 
LXR agonist treatment [167]. Activation of LXR also decreases intestinal absorption of 
cholesterol and appears to also be mediated through the induction of ABC transporters, 
specifically ABCG5 and ABCG8. 
Activation of LXR also has positive effects on glucose metabolism. LXR- 
mediated improvement in glucose tolerance is associated with decreased expression of 
rate limiting enzymes of gluconeogenesis such as phophoenolpyruvate carboxykinase 
(PEPCK) and glucose-6-phosphatase (G6Pase) and the induction of genes for glucose 
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uptake and utilization in the liver and periphery, such as L-GK and GLUT4, respectively 
[168]. The effects of LXR on fatty acid synthesis are mediated through the increased 
expression of SREBP-1, a transcription factor suspected in PI-induced lipodystrophy and 
discussed in section (1.1.4) [169]. The increased production of liver TGs as well as 
transient increases in plasma levels resulting from the upregulation of SREBP remains a 
roadblock in the development of LXR agonists as therapeutics for diabetes. 
 FXR, the counterbalance of LXR action in the liver, is activated by bile acid 
accumulation resulting from the LXR-mediated conversion of cholesterol to bile acids 
[170]. High concentrations of bile acids can be toxic to the cell and FXR functions to 
minimize this potential by inhibiting further production of bile acids. Inhibition of bile 
acid synthesis is achieved by increasing expression of the short heterodimer partner 
(SHP) [171]. SHP represses cyp7A1 expression by binding to promoter sequences and 
preventing further RE binding of activated LXR. FXR also facilitate elimination of bile 
acids through the activation of bile acid transporters such as, the bile salt export pump 
(BSEP) also known as sister of p-glycoprotein (SPGP) and the intestinal bile acid binding 
protein (IBABP) [172, 173]. Interestingly, PXR is also activated by bile acids, especially 
lithocholic acid (LCA) [174]. PXR activation results in inhibition of cyp7A1, similar to 
FXR, although by an unknown mechanism. Recent data suggests FXR may directly 
regulate PXR transcription levels and may serve to promote robust liver detoxification in 
the presence of high levels of bile acids [175]. 
Recent publications concerning FXR and the development of constitutive 
activating and knockout (KO) models have demonstrated that FXR activation has 
positive effects on glucose metabolism and has triggered much activity surrounding FXR 
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as a therapeutic target for diabetes [176]. Positive effects of FXR agonists on glucose 
tolerance are brought about through the hepatic activation of FXR and the resulting 
repression of gluconeogenic genes, PEPCK and G6Pase, and increased hepatic glycogen 
synthesis [177, 178]. In addition to improving glucose tolerance, FXR activation also 
improves serum lipid profiles through suppression of hepatic triglyceride synthesis via 
repression of SREBP-1c and increased expression of lipid metabolism genes such as 
PLTP, LCAT and apoC-II. However, FXR-mediated inhibition of fatty acid synthesis 
may be transient. Prolonged exposure to high levels of bile acids or potent agonists does 
not appear to have the same beneficial effects as short term exposure on plasma lipids 
[179]. SHP-mediated suppression of SREBP-1c via FXR activation appears to be 
overcome through the direct activation of fatty acid synthase (FAS) by FXR. Direct 
activation of FAS by FXR is necessary for sufficient fatty acid synthesis under states of 
cholesterol and bile acid excess in order to continue esterification of cholesterol and 
avoid cholesterol toxicity. Further research is needed in order to determine whether FXR 
agonists will be suitable in the treatment of metabolic diseases or whether the multiple 
gene effects of nuclear receptor activation will provide drug development hurdles as they 
have done in the development of PPARα/γ and LXR agonists [169, 180] . 
 
1.2.2.3 Pregnane X Receptor 
Inclusion of the HIV PI ritonavir in combination therapies has been shown to 
significantly improve circulating concentrations of coadministered drugs [181, 182]. 
Improvement in drug serum concentrations have been attributed to a reduction in overall 
drug metabolism due to direct inhibition of the monoxygenase cytochrome p450 3A4 
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isozyme (cyp3A4) by ritonavir [183]. Cyp3A4 is responsible for the metabolism of more 
than 50% of drugs administered to humans. Pregnane X receptor (PXR) RE sequences 
identified in the promoter region of the cyp3A4 gene have indelibly linked 3A4 
transcriptional regulation to the activation of PXR [184]. Activators of PXR are mainly 
comprised of substrates and inhibitors of cyp3A4, providing a mechanistic loop for 
effective drug clearance [185]. PXR is expressed predominantly in the liver and is 
activated by a broad range of structurally diverse xenobiotics and endogenous ligands. 
PXR REs have been identified in additional p450 enzymes, drug export pumps and phase 
2 drug metabolizing enzymes, implicating PXR as the master regulator of xenobiotic 
metabolism and clearance [186].   
 In addition to its role as a xenobiotic sensor, PXR has been linked to the 
regulation of genes within lipid and cholesterol pathways via activation by endogenous 
sterol metabolites [187-189]. As mentioned in section 1.2.2.2, PXR is activated in the 
presence of high levels of bile acids, specificically LCA, and oxysterols in the liver [174]. 
Activation of PXR under these conditions provides an additional route for elimination of 
cholesterol and bile acids other than through activation of LXR and FXR alone. Target 
gene expression under these conditions is geared towards increasing the livers capacity to 
avoid toxicity associated with elevated levels of cholesterol and bile acids through 
increased expression of export pumps and increased expression of enzymes capable of 
‘inactivating’ toxic components through chemical modifications such as cyps and 
sulfotransferases.  PXR also contributes to liver detoxification efforts by ensuring 
availability of fatty acids for cholesterol ester formation. PXR activation increases 
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expression of the fatty acid transporter CD36 and several accessory lipogenic enzymes, 
such as stearoyl-CoA desaturase-1 (SCD-1) and long chain free fatty acid elongase [187].  
PXR is also implicated in the regulation of gluconeogenic gene transcription. 
Regulation of gluconeogenic enzymes by PXR occurs through crosstalk with the 
forkhead transcription factor, FOXO1 [189]. FOXO1 is an insulin responsive 
transcription factor that increases transcription of gluconeogenic genes such as PEPCK 
and G6Pase. FOXO1 activity is inhibited through insulin signaling upon feeding. PXR 
activation also inhibits FOXO1 activity by blocking the binding of FOXO1 to insulin 
response sequences in target gene promoters. It is speculated that crosstalk regulation at 
FOXO1 may be needed in order to regulate the balance between the cofactors, NADPH 
and NADH. PXR inactivation of gluconeogenesis would increase availability of NADPH 
for use by drug metabolizing enzyme such as CYP3A4 for which NADPH is an essential 
electron donor.  
PXR does not have a necessary role in lipid and glucose homeostasis. However, 
PXR activation has been shown to have a profound effect on the expression and 
activation of key pathway controllers as a consequence of the molecular requirements for 
robust xenobiotic and endobiotic metabolism. Through activation of PXR, xenobiotics 
and steroid intermediates can have a wide reaching effect on lipid and glucose 
homeostasis. HIV PIs are known activators of PXR and have been shown to increase 
expression of cyp3A4 [185]. How activation of PXR by PIs effect expression patterns in 
metabolic pathways is yet to be determined.  
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1.2.2.4 Retinoid X Receptor 
A common link between the nuclear receptors involved in the maintenance of 
energy homeostasis is the requirement of heterodimer formation with the retinoid X 
receptor (RXR) for proper binding of DNA REs and transcription of target genes. The 
RXR family of nuclear receptors is comprised of three isotypes, α, β and γ [115]. RXRα 
is the dominant RXR isoform and the preferred heterodimer partner of metabolic nuclear 
receptors such as the PPARs, LXR and FXR. RXRα is activated by a product of retinol 
metabolism, a derivative of vitamin A known as 9-cis retinoic acid [190]. 50-80% of 
retinoids are stored in liver stellate cells. The remaining 15-20% of retinoids are stored in 
adipose tissue through the LPL-mediated uptake of retinyl esters from chylomicrons and 
direct import from the bloodstream through the cellular retinol-binding protein. In 
addition to retinoids, fatty acids, such as phytanic and docosahexaenoic acids, have been 
recently identified as endogenous activators of RXR [191, 192]. The discovery of RXR 
affinity for fatty acids has brought into question the traditional role of RXR as a 
heterodimer partner.  
Transcriptional activation of heterodimers can occur through ligand-specific 
activation of the ‘sensor’ receptor, ‘non-specific’ activation of RXRα or activation of 
both partners [193]. RXR affinity for fatty acids opens the possibility that RXR, like its 
heterodimer partners, also operates as a sensor of energy metabolism with the potential to 
drive metabolic responses through the concerted activation of RXR-containing 
heterodimers. RXR-specific agonists have been shown to have similar effects as PPARγ 
activating TZDs on glucose and TG levels as well as improvements in peripheral insulin 
resistance in mouse models of diabetes and obesity [194]. The similarity of effects is 
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likely due to the preferentially activation of the RXR/PPARγ heterodimer by RXR 
activators. While there is similarity between RXR agonists and TZDs in improvement of 
diabetes markers, treatment with RXR agonists has the added benefit of preventing 
weight gain usually associated with TZD treatment.  
The importance of RXR as both a retinoid receptor and heterodimer partner is 
made evident through observations of the deleterious effects on survival and metabolism 
in various RXRα KO models.  Whole body RXRα KOs are lethal in utero and display 
myocardial and ocular malformations consistent with fetal vitamin A deficiency 
syndrome, highlighting the role of RXRα in retinoid signaling [195]. Adipocyte-specific 
KO models of RXRα are resistant to obesity and have impaired adipocyte differentiation 
and lipolysis likely due to the lack of PPARγ/RXRα heterodimer formation in these 
animals [196]. Liver-specific KO models of RXRα are viable but have profound effects 
on nearly every metabolic pathway where gene regulation is controlled by a nuclear 
receptor that requires heterodimerization with RXRα [197, 198].  
 
1.3 Thesis Outline  
The specific objectives of this research were two-fold. The first objective was to 
determine direct effects of HIV drugs on the activation of nuclear receptors involved in 
metabolism. Nuclear receptor activation was determined by in vitro methods which 
measure both the receptors ability to recruit coactivator peptides and increase reporter 
gene transcription. HIV drugs which elicited an effect were further evaluated by 
measuring mRNA levels of known target genes in primary hepatocytes. The second task 
was to determine whether utilizing truncated nuclear receptor constructs in receptor 
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activation assays effects the rank order potency and efficacy of known agonists of 
PPARα relative to the full length construct. 
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Chapter 2: Effect of HIV Drugs on the Activation of Metabolic Nuclear Receptors 
 
 
2.1 Introduction 
 
In developed countries, the life expectancy of HIV-infected individuals has 
increased substantially through the use of HAART in the management of HIV infection 
[2-4]. Despite the benefits of HAART, acute adverse events often reduce patient 
compliance and limit the effectiveness of treatment [15, 16]. Patients who are tolerant of 
HAART must remain on a cocktail of HIV drugs for the duration of their lives. Long 
term use of PIs, the lynch pin of HAART therapy, has been linked to the development of 
HIV/HAART-associated dyslipidemic lipodystrophy (HADL) [18]. HADL is associated 
with an increased risk of cardiovascular disease and type 2 diabetes in long-term HIV 
survivors [22-24]. Increased levels of circulating triglycerides and cholesterol and insulin 
resistance are early markers in the development of HADL [20, 21]. HADL also causes 
appearance-related side effects due to abnormal redistribution of fat storage from 
peripheral to visceral adipose [27, 199]. Changes in body fat distribution have a profound 
psychological effect on patients and have been shown to increase the risk of non-
adherence to therapy by 5 fold [29, 30, 200].  
 From the time HADL was first observed in the clinic, researchers have focused 
on uncovering the underlying mechanism in the hope of minimizing side effects of 
current HIV therapies. Observations of altered serum lipid and glucose levels in HADL 
patients indicate that PIs are most likely interfering with effectors of lipid and glucose 
homeostasis. Some of the metabolic processes shown to be impacted by HIV PIs are 
inhibition of GLUT4 mediated uptake of glucose, inhibition of ApoB degradation and 
preadipocyte differentiation and dysregulation of sterol regulatory element binding 
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proteins (SREBPs) [71-73]. However, the redundant nature and complexity of metabolic 
pathways make it difficult to identify clinically relevant cellular mechanisms in the 
pathogenesis of HADL. The high dose of PIs required to achieve therapeutic effects, 
ranging from 300 – 1250 mgs administered 2-3 times daily, further confound the problem 
by increasing the likelihood of multiple off-target interactions [92, 93]. It is apparent 
from both clinical and biochemical evidence that HADL likely results from the disruption 
of multiple pathways involved in energy mobilization, utilization, and storage. The role 
of nuclear receptors as major transcriptional regulators directly affecting the abundance 
of target genes in multiple metabolic pathways and the potential for PI-mediated 
desensitization to intrinsic ligands, make them ideal candidates for investigating the 
pathology of HADL.  
Initial investigations into PI effects on nuclear receptors stemmed from the 
observation that HIV patients with lipodystrophy presented with symptoms similar to 
those found in genetic forms of the disease [18]. Familial partial lipodystrophy type 3 has 
been linked to a P467L mutation in the gene encoding the peroxisome proliferator-
activated receptor gamma (PPARγ) [201, 202] . PPARγ is a member of the PPAR family 
of nuclear receptors whose primary target genes serve as control points in lipid and 
glucose metabolic pathways [156, 203]. Expression of PPARγ is up regulated during 
preadipocyte differentiation and is highly expressed in mature adipocytes where PPARγ 
activation facilitates the uptake and storage of circulating fatty acids through upregulation 
of genes such as aP2, lipoprotein lipase (LPL), fatty acid transport protein (FATP) and 
acyl CoA synthetase [204]. Reduction in fatty acid storage capacity in subcutaneous 
adipose can increase circulating fatty acids and facilitate uptake in non-adipocyte tissues 
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such as skeletal muscle and liver, leading to insulin resistance and peripheral lipoatrophy 
[205] . Conflicting results have been reported on the effects of PIs on PPARγ function.  
Saquinavir and indinavir have been shown to inhibit differentiation of preadipocytes in 
culture, a function attributed to PPARγ. However, levels of aP2 expression, a known 
PPARγ target gene, were found to be unaffected by exposure to saquinavir and indinavir 
[105, 106]. Lenhard et al. also reported decreased adipogensis, lipogenesis and increased 
lipolysis upon exposure of adipocytes to saquinavir, ritonavir and nelfinavir but with an 
associated decrease in mRNA levels of adipocyte markers, aP2 and LPL [107]. In 
contrast, similar experiments performed by Ragnathan and Kern showed decreased 
activity of LPL in adipocytes without a decrease in mRNA levels upon exposure to 
saquinavir suggesting PIs may act through alterations in post-translational processing 
rather than transcription [108]. PI effects on lipolysis, lipogenesis and expression of aP2 
and LPL are opposite to effects observed for PPARγ agonists in cultured adipocytes. 
Further, treatment of patients with rosiglitazone and metformin, known agonists of 
PPARγ, provides at least moderate improvements in both insulin resistance and fat 
distribution [109]. Despite circumstantial evidence suggesting involvement of PPARγ in 
HADL, direct interaction between PIs and PPARγ have yet to be demonstrated.  
 Inclusion of ritonavir in combination therapies has been shown to significantly 
improve circulating concentrations of coadministered drugs [181, 182]. Improvement in 
drug serum concentrations have been attributed to a reduction in overall drug metabolism 
due to direct inhibition of the monoxygenase cytochrome p450 3A4 isozyme by ritonavir 
[183]. Pregnane X receptor (PXR) response element (RE) sequences identified in the 
promoter region of the 3A4 gene have indelibly linked 3A4 transcriptional regulation to 
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the activation of PXR [184]. Ritonavir, as well as other PIs, has been shown to activate 
PXR-mediated gene transcription and increase levels of 3A4 [185]. RE sequences have 
also been identified in additional p450 enzymes, drug export pumps and phase 2 drug 
metabolizing enzymes, implicating PXR as the master regulator of xenobiotic 
metabolism and clearance [186].  In addition to it role as a xenobiotic sensor, PXR has 
recently been linked to the regulation of genes within lipid and cholesterol pathways via 
activation by endogenous sterol metabolites [187-189]. How activation of PXR by PIs 
effect expression patterns in these pathways has yet to be determined.  
Based on the broad effects of nuclear receptor modulation on metabolic pathways 
and prior evidence of PI interactions with PXR, we set out to explore the possibility of 
HIV drug interactions with nuclear receptors that were either previously uninvestigated 
or PI interaction was deemed inconclusive. Selection of the panel members FXR, LXRα, 
RXRα, PXR and PPAR α,γ, and δ, was based on relevance of target gene activity in 
metabolic pathways and potential for alterations in expression levels resulting in 
symptoms of HADL.  
Our investigation into HIV drug effects on nuclear receptor binding and activation 
suggest that HADL symptoms, particularly dysfunctions in glucose processing, may be a 
direct result of PI inhibition of PPARγ activation, directly impacting expression levels of 
two key elements in glucose stimulated insulin secretion (GSIS) and glucose metabolism.    
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2.2 Materials and Methods 
 
2.2.1 Reagents 
 
All solvents and buffer components were purchased from Sigma unless otherwise 
noted. All media and components for transfections were purchased from Invitrogen 
except for charcoal-striped fetal calf serum which was purchased from Hyclone. Ligands 
were purchased from Biomol except for ciprofibrate, TO901317 and GW7647 which 
were purchased from Sigma. The coactivator peptides, biotinylated steroid receptor 
coactivator -1 M2 (bSRC-1 M2), biotinylated CREB binding protein (bCBP) and 
biotinylated PPARγ coactivator −1 (bPGC-1), were synthesized and prepared to 95% 
purity by Synpep Corp (Table 1). Europium-labeled anti-GST antibody (Eu-αGST) was 
purchased from CIS-Bio US Inc. Allophycocyan-labeled streptavidin (APC-SA) was 
purchased from Perkin Elmer. The HIV drug panel was purchased from Sequoia 
Research Products Ltd. (Table 2). Primary hepatocytes were obtained from Cellzdirect. 
 
Table 1. Sequences of Coactivator Peptidesa,b. 
Coactivator Peptide Sequence and modifications 
bSRC-1 M2 Biotin-Ahx-CPSSHSSLTERHKILHRLLQEGSPS-CONH2 
bPGC-1 Biotin-Ahx-DGTPPPQEAEEPSLLKKLLLAPANT-CONH2 
bCBP Biotin-Ahx-SGNLVPDAASKHKQLSELLRGGSGS-CONH2 
a Underlined sequence indicates LXXLL motif involved in receptor binding 
b Ahx = aminohexanoyl 
 
 
  45 
Table 2. HIV drug panel. 
Protease Inhibitors (PIs) 
 
Ritonavir 
Saquinavir 
Indinavir 
Nelfinavir 
 
Nucleoside Reverse Transcriptase 
Inhibitors (NRTIs) 
 
 
Zidovudine 
Zalcitibine 
Lamivudine 
Stavudine 
 
Non-Nucleoside Reverse 
Transcriptase Inhibitors (NNRTIs) 
 
Efavirenz 
Nevirapine 
 
 
 
 
2.2.2 Cloning and Expression of the Nuclear Receptor Panel 
 The panel of nuclear receptors was amplified from cDNA utilizing the 5’ and 3’ 
primers listed in Table 3. PCR reactions were performed using a combination of GC-2 
and HF-2 PCR polymerase mixes (BD Clontech). The purified PCR products were 
cloned into Invitrogen’s Gateway entry vector, pENTR / D-TOPO. Single clones were 
selected based on their resistance to kanamycin and the isolated plasmids, pENTR:X (X = 
nuclear receptor), were sequenced to confirm complete gene insertion. The pENTR: X 
plasmids were then recombined with the Gateway destination vector pDEST15 using LR 
clonase as per manufacturer’s instructions. The pDEST15 expression vector confers an 
N-terminal GST tag in-frame with the receptor protein for use in purification and 
detection. Single colonies containing pDEST15: X plasmids were selected based on 
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resistance to carbenicillin. pDEST15: X plasmids were then transformed into the 
expression host, BL21(DE3) pLysS,  for protein expression.  
 
Table 3. List of Primers and cDNA for PCR Amplification. 
Receptor 
(Genbank accession #) 
cDNA 
source Amplification primers* 
PPARα  
(L02932) [206] kidney 
5’CACCATGGTGGACACGGAAAGC 3’ 
5’CTAGTACATGTCCCTGTAGATCTCCTGCAGTAG 3’
PPARα LBD 
(L02932) kidney 
5’ CACCTCACACAACGCGATTCGTT 3’ 
5’CTAGTACATGTCCCTGTAGATCTCCTGCAGTAG 3’
PPARγ  
(U79012) [207] adipose 
5’CACCATGGGTGAAACTCTGGGAG 3’ 
5’CTAGTACAAGTCCTTGTAGATC 3’ 
 
PPARδ  
(L07592) [208] placenta 
5’CACCATGGAGCAGCCACAGGAGG 3’ 
5’TTAGTACATGTCCTTGTAGATCTC 3’ 
 
FXR  
(U68233) [170] kidney 
5’CACCATGGGATCAAAAATGAATCTCATTG 3’ 
5’TCACTGCACGTCCCAGATTTCAC 3’ 
 
LXRα  
(U22662) [209] placenta 
5’CACCATGTCCTTGTGGCTGGGGGCCCCTG 3’ 
5’TCATTCGTGCACATCCCAGATCTCAG 3’ 
 
RXRα LBD 
Ser225- stop263
(X52773) [210] 
kidney 
5’CACCAGCGCCAACGAGGACATGCC 3’ 
5’CTAAGTCATTTGGTGCGGCGCCTCC 3’ 
 
PXR 
 (AF061056) liver 
5’ACGCGTCGACTTATGGAGGTGAGACCCAAAG 3’ 
5’ATAAGAATGCGGCCGCTCAGCTACCTGTGA 3’ 
*underlined sequence indicates native start and stop codons 
 
 
 
Transformed 1 litre cultures were induced during exponential growth phase, 
OD600 of 0.4 to 0.6, with fresh 400 μM IPTG and grown at room temperature for 4 hours. 
Cells were harvested by centrifugation at 12,000g. Cell pellets were frozen at –20 ºC and 
lysed by thawing on ice. 50 ml of Buffer A containing 50 mM Tris pH 8.0, 50 mM KCl, 
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1 mM EDTA, 1 mM DTT, 10% glycerol and 1 mM PMSF were added to the cell pellets. 
Cell aggregates were disrupted by passage through an 18-gauge syringe or homogenizer. 
Deoxyribonucease I was added to the lysate at a final concentration of 20 μg/ml and 
incubated at 37 ºC for 2 hours. The cell lysate was clarified by centrifugation at 50,000g 
and filtered through a PES 0.22 μM filter prior to purification. Purification of the GST-
receptor fusions was performed using Glutathione 4B sepharose (Amersham 
Biosciences). All column equilibration and washing were performed with Buffer A. 
Proteins were eluted from the column using Buffer A with the addition of 20 mM 
glutathione pH 8.0. Protein concentrations were determined by Bradford method and 
purity assessment was determined by SDS-PAGE and western blot analysis using 1:1000 
anti-GST mouse antibody. 
 
2.2.3 Coactivator Recruitment Assay 
 Agonist-HIV drug panel and known ligands 
The panel of HIV drugs was evaluated for agonist effects on coactivator 
recruitment for each receptor. Each receptor assay was validated by titration with 
reported ligand. All reagent concentrations (GST-receptor, APC-SA and coactivator 
peptide) were optimized for maximal assay signal. The coactivator recruitment assay was 
performed for each nuclear receptor in the panel with the exception of PXR. HIV drugs 
were evaluated against PXR using the cell-based reporter method only. 
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Table 4. Ligand Kds for Coactivator Recruitment Assay. 
 
Receptor 
Coactivator 
peptide Ligand 
Saturating
ligand 
(nM) 
HTRF Kd 
(nM) n=3 
Lit. Kd 
(nM) 
 
 
Titrations of the HIV drug panel and known ligands were prepared at 100 x 
concentration by performing 8 point two-fold serial dilutions in DMSO with a top 
concentration of 100 μM (1x). 1 μl of the HIV drug or ligand titrations were dispensed 
into 96-well black optiplates (Perkin Elmer). 1 μl of DMSO was dispensed to each 
negative control well. 1 μl of 100 x saturating concentrations of ligand for each receptor 
were dispensed into the positive control wells (Table 4). 99 μl of assay mix containing 
 
PPARα 
 
 
bCBP, 
bSRC-1 M2 
[211] 
GW7647 100 5.6 ± 1.4 
 
6 
[212] 
 
PPARγ 
 
 
bSRC-1 M2 
[213] 
Troglitazone 10 000 
 
1 134 ± 176 274-300 
[214, 215] 
 
PPARδ 
 
 
 
bPGC-1 
[213] 
 
L165,041 10 000 
 
71 ± 4.4 320, 6 
[216],[157] 
 
RXRα 
LBD 
 
 
bPGC-1 11.4 ± 2.1 
 
[217] 
 
9-cis-retinoic acid 100 14 
[218] 
 
LXRα 
 
 
 
bSRC-1 M2 
[219] 
 
24(s)-
hydroxycholesterol 1 000 89.5 ± 25 
 
70 
[220] 
FXR 
 
 
bSRC-1 M2 
[221] 
 
Chenodeoxycholic 
acid   100 000 
 1 125 ± 
50.5 4 500 
[222] 
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100 nM GST-receptor, 100 nM APC-SA, 3 nM Eu-αGST antibody and 600 nM 
coactivator peptide (Table 4) in 50 mM Tris pH 8.0, 50 mM KCl, 1 mM EDTA, 1 mM 
DTT and 1 mg / ml BSA was dispensed to each well [213]. The final assay volume was 
100 μl  with 1 % total DMSO. The content of the wells were mixed by pippetting and 
spun at 300g to remove bubbles. The plates were covered and incubated at room 
temperature for 2 hours [216]. Fluorescence was measured by excitation at 340 nm and 
collection of emission at 615 nm and 665 nm. Measurements were performed on the 
Perkin Elmer Fusion using the factory settings for time-resolved fluorescence. Nelfinavir 
mediated FXR activation and recruitment of bCBP and bPGC-1 coactivator peptides was 
also evaluated using the methods outlined above. All experiments were performed in 
duplicate. 
 
Antagonist-HIV drug panel 
The HIV drug panel was evaluated for antagonist effects on the nuclear receptors 
by measuring the interference these compounds have on ligand-induced coactivator 
recruitment. Titrations of the HIV protease inhibitors were prepared at 100 x final assay 
concentration by performing 8 point two-fold serial dilutions in DMSO with a top 
concentration of 100 μM (1x). All HIV compounds and ligands were prepared as stock 
solutions at 100x of the initial concentration. 1 μl of the HIV drug titrations were 
dispensed into 96-well black optiplates (Perkin Elmer). Along with the HIV drug, 1 μl of 
ligand at 1.8 Kd  (Table 4) was dispensed in each well. The negative control wells 
received 2 μl of DMSO and the positive control wells received 1 μl of DMSO and 1 μl of 
100 x 1.8 Kd ligand. 98 μl of assay mix containing 100 nM GST-receptor, 100 nM SA-
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APC, 3 nM Eu-αGST and 600 nM coactivator peptide (Table 4) in 50 mM Tris pH 8.0, 
50 mM KCl, 1 mM EDTA, 1 mM DTT and 1 mg / ml BSA was dispensed to each well. 
The final assay volume was 100 μl with 2 % total DMSO. All experiments were 
performed in duplicate. Plates were handled identically as described for the agonist assay. 
In addition to the bCBP peptide, PI effects were also evaluated on PPARα recruitment of 
the bSRC-1 M2 peptide. 
 
2.3.4 Reporter Gene Assay 
Preparation of stable reporter cell line 
pG5luc, GenBank accession # AF264724, is a reporter vector containing the Gal4 
RE upstream from a fire fly luciferase reporter gene (Promega Corp., Madison, WI). The 
plasmid was converted into a stable reporter plasmid by cloning a neomycin resistance 
gene at the BamHI (2142) / SalI (2148) sites. Wild type HEK293 (ATCC# CRL-1573) 
cells were transfected with the pG5luc+neo plasmid using lipofectamine according to the 
manufacturer’s instructions. Single clones were selected using 800 μg /ml geneticin. 
Transformed cells were grown in DMEM with 4.5 g / L glucose and 25 mM Hepes 
supplemented with 10 % charcoal stripped fetal bovine serum, penicillin-streptomycin 
and glutamine. Cells were maintained at 37°C in a 5 % CO2 humidified incubator.  
 
Preparation of Gal4 DBD-Nuclear receptor chimeras 
pBIND vector, GenBank accession # AF264722, contains a multiple cloning site 
downstream from the yeast Gal4 DBD (Promega Corp., Madison, WI). The pBind vector 
was converted into a Gateway destination vector through the insertion of Reading Frame 
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B (rfb) at the EcorV site (1594) as per manufacturer’s instructions. The pENTR: X entry 
plasmids generated previously for expression of GST-tagged receptor in the coactivator 
recruitment assay were recombined with the converted destination vector pBIND: rfb 
using LR clonase. All constructs were 5’ sequence confirmed for correct orientation of 
gene.  
 
Preparation of hPXR and CYP3A4-response element reporter plasmid 
Preparation of the CYP3A4 reporter plasmid, p3A4-362 (7836/7208 Ins), was 
described previously [223] and constructed with the following restriction site usage. The 
response element sequence, -7836/-7208, was cloned into pGL3-basic (Promega Corp., 
Madison, WI) at KpnI/NheI restriction sites and the proximal promoter, -362/+53, was 
inserted at XmaI/ Hind III restriction sites. Full-length human pregnane X receptor was 
amplified from liver cDNA and cloned into pcDNA 3.1 / +Zeo (Invitrogen) at NheI/ XbaI 
restriction sites using the primers listed in Table 3. 
 
Cell line transfection 
 pG5luc + neo HEK293 stables were batch transfected with pBind: X plasmid at 
200 ng /μl using lipofectamine as per manufacturer’s protocol. The cells were plated at a 
concentration of 5 x 105 cells per well into black-well clear bottom tissue culture treated 
plates. The transfected cells were incubated for 24 h, after which an additional 100 μl of 
media was added to all wells. The same procedure was performed for the cotransfection 
of pcDNA3.1:hPXR and p3A4-362 (7836/7208 Ins) into HepG2 cells. 
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Reporter assay-Agonist mode 
The panel of HIV drugs was evaluated for agonist effects on receptor-mediated 
reporter gene transcription. Known ligands for the panel of nuclear receptors listed in 
Table 5 were also tested for direct comparison to HIV drug-induced reporter gene 
transcription levels and to ensure accurate determination of EC50 values for use in the 
antagonist mode assay. 
Table 5. Ligand EC50s for Cell-Based Gal4 Reporter Assay. 
Receptor Ligand Cell-Based EC50 (nM) N ≤ 3 Lit. EC50 (nM) 
PPARα Ciprofibrate 4 613 ± 1 215      6 000  [211] 
 
PPARγ Troglitazone 1 512 ± 269       550  [224] 
PPARδ L165,041 135 ± 13       530  [224] 
 
RXRα LBD 9-cis-retinoic acid 26.3 ± 7.0        20  [225] 
 
LXRα TO901317 168 ± 34        50  [166] 
 
FXR Chenodeoxycholic acid 25 686 ± 3 240    20 000  [170] 
 
         PXR 
 
Rifampicin 953 ± 54     1 000  [184] 
 
 
The ligand and HIV drug titrations were prepared by performing 8 point two-fold 
serial dilutions in DMSO. The negative control for all constructs was 100 % DMSO and 
positive controls contained saturating concentration of ligand. 1 μl of the 1000 x drug 
plate were transferred well to well to a new 96-well polypropylene plate. 200 μl of 
growth media was added to each well and mixed thoroughly by pipetting. 50 μl of media: 
drug was added to the respective well in the assay plate containing transfected cells (final 
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volume 250 μl, 0.1 % DMSO). The cells were returned to the incubator for another 24 
hours. Luciferase measurements were conducted using Bright GLO reagents (Promega 
Corp., Madison, WI) All media was removed from the wells and a 1:1 mixture of phenol 
red free media and Bright GLO substrate were added at a final volume of 200 μl. The 
plates were placed on an orbital shaker for 2 minutes to aid in cell lysis then read on a 
Perkin Elmer Victor V using the factory settings for luminescence readings.  
 
Reporter assay-Antagonist mode 
Dilution plates were prepared at concentrations 2000x the final assay 
concentration in DMSO for both the HIV drug panel and receptor specific agonist. The 
highest concentration of HIV drug evaluated in experiments was 100 μM. The negative 
and positive controls for the HIV drug dilution plate were 100 % DMSO. A 0.5 μl aliquot 
from the HIV drug dilution plate was transferred well to well to a new 96-well 
polypropylene plate. The receptor specific agonist plate was prepared by dispensing 100 
% DMSO to negative control wells and agonist concentrations equal to the EC80, 
calculated from Table 5, of the receptor specific ligand to all remaining wells. The 
negative control for the agonist plate was also 100 % DMSO. 0.5 μl of the 2000 x ligand 
dilution plate was transferred well to well to the same polypropylene plate that the HIV 
drugs were dispensed.  Assay plates were handled identically to procedure described 
above for the agonist mode assay 
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2.2.5 Cell Toxicity Assays 
Cellular toxicity of HIV protease inhibitors was determined for both primary 
hepatocytes and the pG5luc + neo HEK293 cell line. Toxicity was assessed using two 
distinct assay techniques. Apo-ONE homogeneous caspase-3/7 and CellTiter-Glo assays 
were performed as per manufacturer’s protocol (Promega Corp., Madison, WI). 
Hepatocytes were received from Cellzdirect plated in 96-well plates coated with collagen 
and overlayed with Matrigel.  pG5luc + neo HEK293 cells and drug plates were prepared 
as described for the agonist mode cell-based assay with the exception of lipofectamine 
transfection of the Gal4LBD-receptor plasmid. Drugs were incubated with cells for ~ 24 
hours prior to assessment of drug-induced toxicity. 
The CellTiter-Glo assay reagents were prepared by mixing CellTiter-Glo 
substrate with equal volume of phenol red-free media. Media containing drug was 
removed from all wells and replaced with 200 μl of CellTiter-Glo substrate: media mix. 
Assay plates were mixed for 2 minutes on an orbital shaker and incubated at room 
temperature for 10 minutes Well luminescence was read on a Perkin Elmer Victor V 
using the factory settings for luminescence readings.  
Cellular caspase activity was determined using the apo-ONE homogeneous 
caspase-3/7 assay. 100 μl of apo-ONE substrate were added to all wells for a final 
reaction volume of 200 μl. The assay plate was incubated at room temperature with 
shaking for 90 minutes Caspase activity was determined by measuring the fluorescence 
signal generated by excitation at 485 nm and emission at 530 nm on a Perkin Elmer 
Victor V. 
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2.2.6 Gene Expression Analysis 
PI treatment of primary hepatocytes and preparation of RNA 
Fresh primary hepatocytes were received from Cellzdirect plated in 6-well format 
on collagen substrata with matrigel overlay. Cells were maintained in Modified Chee’s 
media supplemented with dexamethasone, plus ITS and penicillin-streptomycin 
(CellzDirect) at 37°C in a 5 % CO2 humidified incubator. PI selection and concentrations 
were determined from results obtained in the cell toxicity assay. 15 μM of ritonavir, 15 
μM saquinavir with or without 3 μM troglitazone and DMSO control were added to 
hepatocytes (final DMSO concentration, 0.1%). Hepatocytes were incubated with drug 
containing media for 24 hours. The hepatocytes were harvested and total RNA extracted 
using Qiagen’s RNAeasy RNA isolation kit. Concentration and purity of samples were 
determined by OD260/280 measurements. 
 
Gene chip analysis 
RNA isolated from hepatocytes treated with DMSO, saquinavir and ritonavir 
were evaluated for drug-induced changes in mRNA transcript levels using GE CodeLink 
Whole Human Genome Arrays (55K). Sample processing was performed by the Center 
for Environmental Health, Science and Technology at the University of Massachusetts 
Boston. Briefly, 2 μg of high quality total RNA was reverse transcribed to produce first-
strand and subsequently, second-strand cDNA. The double-stranded cDNA was used as a 
template for in vitro transcription utilizing Ambion's T7 MEGA script reagents and 
Biotin-11-UTP (PerkinElmer). The resulting biotin labeled cRNA was recovered and 
purified with Qiagen’s RNeasy and quantified. 10 μg of the labeled cRNA, along with 
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bacterial controls, were hybridized overnight at 37°C to the arrays. After the overnight 
incubation and a stringent wash at 47°C, the array was incubated with Alexa fluor 
conjugate. After a three room temperature washes, the slides were spun dry, inspected for 
gross interference and scanned with a Packard ScanArray 5000 HT, standard setting for 
CodeLink (100 % laser/ 60 PMT). The generated images were then processed.  
 
Statistical evaluation of gene chip data 
The array images were processed using the GE CodeLink expression analysis 
software. The probe signals were normalized to the median probe intensity of the array. 
The normalized intensities for each sample were grouped into two classes designated 
treatment 1 (control) and treatment 2 (ritonavir or saquinavir). The two sided, unpaired t-
test were obtained for each gene probe along with the maximum signal in any sample and 
the ratio of the average experimental signal to the average control signal 
(AVERAGE(treatment)/ AVERAGE(control)). Genes with p-values ≤ 0.05 were 
extracted from both treatment groups. Gene sets were then segregated according to 
known association with either PPARα, PPARγ, SREBP or PXR. Transcriptional 
dependence was base on literature determinations of response element sequences and/or 
increased gene transcription due to receptor specific ligands or transgenic models [186, 
226, 227]. 
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Quantitation of GLUT2 and GK mRNA levels 
Total RNA from each sample was quantified and quality check with Agilent 2100 
Bioanalyzer (Agilent Technology). 1 μg of total RNA was treated with DNase I 
(Ambion, Inc) to remove contaminating DNA from RNA samples. 
1 μg of total RNA from each sample was used for each reaction with or without 
reverse transcriptase (RT) using RETROscript Kit from Ambion (Ambion, Inc). RT 
reactions were carried out as follows: 1 µg of total RNA (in 5-9 µl nuclease-free water) 
was mixed with 2 µl Random Decamers and incubated at 70°C for 3 minutes.  After 
cooling on ice, the solution was mixed with 2 µl 10X RT buffer, 4 µl of dNTP mix, 1 µl 
RNase inhibitor and 1 µl of MMLV-RT and incubated for 60 minutes at 44°C. Reactions 
were terminated by heating to 92 °C for 10 minutes. After a preliminary RT-PCR assay 
amplifying the 18S rRNA and GLUT2 and glucokinase (GK) to assess integrity, cDNA 
was stored at –85 oC until required for real-time PCR. 
Primer pairs were designed using Primer Express (Version 1.5, PE Applied 
Biosystems, Foster City, CA) as close as possible to the 3'-coding region of target gene 
sequences obtained from GenBank. Where possible, primers were designed based on 
manufacturer’s guidelines, and as described [228]. QuantiTech Primer Assays for 
GLUT2 and GK (QIAGEN) were used, while for the 18S rRNA the primers used were 
18S-FP 5'-GTCTGTGATGCCCTTAGATG-3' and 18S-RP 5'-
AGCTTATGACCCGCACTTAC-3'. Amplicons were between 88 (GLUT2), 85 bp (GK) 
and 177 base pairs (18S rRNA). GLUT2 and GK primers were checked for efficient 
amplification using cDNA generated from whole blood samples. The resulting PCR 
products were run on a 2 % agarose gel to verify amplification of a correct sized product.   
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SYBR-Green assays for each tissue sample as well 18S rRNA were performed in 
triplicate on cDNA samples in 96-well optical plates on an ABI Prism 7000 Sequence 
Detection system (PE Applied Biosystems) according to the manufacturer’s protocol.  
For each 25 µl SYBR-Green reaction, 10 ng cDNA (5µl ) was mixed with 4.5 µl PCR-
grade water, 12.5 µl 2x Power SYBR-Green PCR Master Mix (PE Applied Biosystems), 
0.5 µl forward primer (300 nM) and 0.5 µl reverse primer (300 nM). The PCR cycle 
condition was as follows: an initial step of 2 minutes at 50 °C was used for AmpErase 
incubation followed by 10 minutes at 95 °C to inactivate the AmpErase and to activate 
the Taq polymerase. This was followed by a denaturation step of 95 °C for 15 seconds 
and finally annealing/extension at 60 °C for 1 minute for 45 cycles. 
 
RT-PCR data analysis (Comparative CT) 
All SYBR-Green PCR data were collected using Sequence Detector Software 
(SDS version 2.0; PE Applied Biosystems. For every sample, an amplification plot was 
generated showing the increase in the reporter dye fluorescence (∆Rn) with each cycle of 
PCR. A CT value, defined as the number of PCR cycles required for the fluorescence 
signal to exceed the detection threshold value [228, 229] based on the variability of base 
line data in the first 15 cycles, was calculated for each reaction. CT values were exported 
into Microsoft Excel worksheets for further analysis.  
The correlation between the CT value and the fold difference in the concentration 
was determined individually for each primer set. When PCR efficiency is 100% the CT 
values of two separate genes can be compared (ΔCT) and the relative fold difference can 
be determined. This was carried out using the Comparative CT Method (Separate Tubes) 
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as defined in the ABI analysis manual. The amount of target, normalized to an 
endogenous reference and relative to a calibrator is given by: 
2-ΔΔ CT
 
For the ∆∆CT calculation to be valid, the efficiency of the target and the efficiency of the 
reference amplification must be approximately equal. The absolute value of the slope of 
log input amount vs. ∆CT should be <0.1. The ∆ CT value is determined by subtracting 
the average 18S RNA CT value from the average GLUT2 and GK CT value. The 
calculation of ∆∆CT involves subtraction by the ∆CT calibrator value. The standard 
deviation of the difference is calculated from the standard deviation of the GLUT2 and 
GK and 18S RNA values using the following formula: 
                                                     22
2
1 sss +=  
The result represents mean and standard deviation of triplicate samples as reported 
earlier.  Each experiment was repeated three times.  
 
2.3 Results 
2.3.1 Coactivator Recruitment Assay 
Coactivator recruitment – HIV drug panel and ligands 
The coactivator recruitment assay is a cell-free assay that is used to measure the 
potential activation of a receptor through binding of coactivator peptides. Positive 
interactions between a ligand and receptor result in positive changes in receptor 
conformation that allow binding of coactivators to coactivator binding sites located in the 
AF-2 region [230].  Cellular requirements for receptor-mediated up-regulation of target 
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gene transcription allow for the use of coactivator peptide recruitment as an indicator of 
receptor activation in a cell-free format. Kd values were obtained for each receptor and 
it’s ligand in the panel to ensure proper evaluation of HIV drugs in the antagonist assay 
and to provide validity to our assay methods. Kd values obtained in the coactivator 
recruitment assay are listed in Table 4 and were calculated by fitting data to equation 1 
where y is the percent activity, x is the corresponding concentration and h is the Hill 
coefficient. 
         
h
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Overall, there was less than two-fold difference between the experimental and 
literature Kd values. The experimental Kd for troglitazone and CDCA were calculated to 
be within 4-5 fold of the literature values. The apparent discrepancy between Kd values is 
most likely an effect of differences in receptor construct design and/or the type of assay 
format used in determining the literature Kd.  
The HIV drug panel was tested to determine whether the selected HIV drugs have 
the capacity to bind and activate receptors. The HIV drugs tested were considered to be 
ineffective as an agonist if the % control at the highest concentration tested did not 
exceed 30 %. Data obtained from the agonist mode coactivator recruitment experiments 
suggest that the PI, nelfinavir, activates FXR as demonstrated by the dose dependent 
increase in coactivator recruitment. Receptor activation by nelfinavir was found to be 
exclusive to FXR (Table 6).  The remaining PIs, NNRTIs or NRTIs did not activate any 
receptor greater than 30 % of control. Dose response data indicate that nelfinavir is a full 
and potent agonist of FXR with an apparent EC50 of 184 ± 11.3 nM. The potency of 
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activation was dependent on the coactivator peptide used in the experiment. Substitution 
of bSRC-1 M2 peptide for either bPGC-1 or bCBP in the assay resulted in a 10 or 20 fold 
decrease in the potency of activation by nelfinavir (Figure 5) 
 
Table 6. Agonist Results for HIV Drugs Tested Against GST-Receptor Panel in HTRF Coactivator 
Recruitment Assay. 
 
 R itonavir N elfinavir Saquinavir Indinavir 
 K d (nM ) 
%  
Control 
K d 
(nM ) 
%  
Control 
K d 
(nM ) 
%  
C ontrol 
K d 
(nM ) 
%  
Control 
PPA R α  - - - - - - - - 
PPA Rγ  - - - - - - - - 
PPA R δ  - - - - - - - - 
L X R α  - - - - - - - - 
F XR  - - 126 ± 11.3  93 ± 2 - - - - 
R X R α  - - - - - - - - 
N ote: -   <  30 %  control, K d not calculated 
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bCBP 4183 ± 1277 
 
 
Figure 5. Nelfinavir Activation of FXR with Different Coactivators. Coactivator recruitment levels 
using either bSRC-1 M2, bPGC-1 or bCBP were measured in the presence of nelfinavir and compared to 
levels obtained with saturating concentrations of CDCA. Data is plotted as % control versus concentration 
of nelfinavir. Each data point is the mean of two determinations with error bars representing the standard 
deviation. 
 
 
The HIV drug panel was also tested to determine whether HIV therapies have the 
capacity to interfere with ligand-induced coactivator recruitment. Antagonist effects by 
the panel would result in reduced coactivator recruitment in the presence of subsaturating 
agonist concentrations (1.8 Kd or EC80). Maximum % inhibition values reported in Table 
7 were calculated from fluorescence ratios obtained at the highest drug concentrations 
(100 μM). IC50 values were calculated by fitting data to equation 1. In cases where a full 
dose response was not obtained, maximal inhibition levels were estimated by 
constraining the Hill coefficient (h) to 1. An HIV drug was considered to be ineffective as 
an antagonist if the % inhibition at the highest concentration tested did not exceed 30 %. 
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Results from the coactivator recruitment assay indicate that the PI class of drugs 
from the HIV drug panel, with the exception if indinavir, behave as antagonist against 
distinct members of the receptor panel at micromolar concentrations (Table 7). The 
NNRTI efavirenz was the only non-PI to show antagonist activity against the receptor 
panel. Reduction of ligand-induced coactivator recruitment by efavirenz was observed 
across the entire receptor panel at 100 μM.  
 
Table 7. Antagonist Results for HIV Drugs Tested Against GST-Receptor Panel in HTRF                                      
Coactivator Recruitment Assay. 
 R ito n a v ir  N e lf in a v ir  S a q u in a v ir  In d in a v ir  E fa v ire n z  
 IC 5 0  (u M ) %  IN H  
IC 5 0 
(u M ) %  IN H  IC 5 0  (u M ) %  IN H  
IC 5 0  
(u M ) 
%  
IN H  
IC 5 0  
(u M ) 
%  
IN H  
P P A R α  -  -  > 1 0 0  8 1  4 3  ±  1 1  5 4  ±  1 .4  1 3  ±  2 .1  7 5  ±  1 .6  2 6  ±  7 .8  1 3 2  ±  2 1  
P P A R γ  -  -  > 1 0 0  5 0  
P P A R δ  -  -  -  -  -  -  -  -  > 1 0 0  9 0  
L X R α  >  1 0 0  3 4  ±  2 .8  >  1 0 0  5 7  ±  1 0 .6  -  -  > 1 0 0  8 7  
F X R  >  1 0 0  2 7  ±  9 .1  -  -  >  1 0 0  4 4  ±  1 5 .5  -  -  > 1 0 0  1 9 0  
R X R α  
L B D  -  -  -  -  -  -  -  -  > 1 0 0  3 5  
3 8  ±  6 .2  3 7  ±  9 .1  9  ±  1 .9  5 3  ±  4 .2  8  ±  4 .5  1 0 2  ±  0 .7  
1 9  ±  8 .2  5 0  ±  6 .3  
-  =  <  3 0  %  in h ib itio n , IC 5 0 n o t c a lcu la te d   
3 0 %  in h ib itio n  an d  IC 5 0  ca lcu la ted   
 
V a lu es  in  re d  =  >  
 
 
The most robust PI antagonist effects were observed within the PPAR receptor 
family, specifically PPARα and PPARγ (Figure 6). Saquinavir exhibited full antagonism 
of ligand-induced recruitment for both receptors. The >100 % inhibition value obtained 
for PPARα indicates that, in addition to ligand-induced coactivator recruitment, 
saquinavir also blocks constitutive coactivator recruitment. Nelfinavir inhibited 
coactivator recruitment in a dose-dependent manner but only showed partial inhibition of 
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agonist activity. The premature plateau observed in the nelfinavir titrations occurs at 
concentrations approaching 50-100 μM for both PPARγ and PPARα and can be 
explained several ways. The effect is likely caused by compound solubility but could also 
be explained by a mechanism involving non-competitive antagonism. Ritonavir inhibited 
coactivator recruitment in a dose-dependent manner but with a lower IC50 values and % 
inhibition than both saquinavir and nelfinavir. It is interesting to note that while several 
PIs inhibited PPARα and PPARγ, there appeared to be no effect on PPARδ. 
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Figure 6. PI Inhibition of PPAR Family Activation. PPAR family member α, γ and δ were evaluated in the HTRF antagonist mode coactivator recruitment 
assay. The agonists employed in the assay were GW7647 (PPARα), troglitazone (PPARγ) and L165,041 (PPARδ). % inhibition values were obtained by 
comparing the level of coactivator recruitment in the presence of both PI and subsaturating agonist with levels obtained with agonist only. Data is plotted as % 
inhibition of coactivator recruitment versus concentration of PI. Each data point is the mean of two determinations with the error bars representing the standard 
deviation. 
  
65 
  66 
In order to determine whether the type of coactivator peptide influences the 
antagonist effects of PI on PPARα, bSRC-1 M2 peptide was substituted for bCBP in the 
coactivator recruitment assay. Saquinavir, nelfinavir and ritonavir were found to interfere 
with PPARα recruitment of bSRC-1 M2 peptide, similar to the effects observed with the 
bCBP peptide (Figure 7). Saquinavir interfered with both ligand-induced and constitutive 
bSRC-1 M2 recruitment by PPARα, though the response was slightly higher than for 
bCBP. Nelfinavir inhibited PPARα recruitment of the bSRC-1 M2 coactivator and was 
25% greater than levels achieved with bCBP. The premature plateau in the nelfinavir 
antagonism of PPARα coactivator recruitment of bCBP was also observed in the 
recruitment of bSRC-1 M2. Ritonavir was unaffected by the type of coactivator used in 
the assay. 
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Figure 7. Inhibition of PPARα Activation using bSRC-1 M2 Coactivator Peptide. The bSRC-1 M2 
peptide was substituted for bCBP to evaluate whether coactivator type influences potency of PI inhibition 
of PPARα activation. % inhibition values were obtained by comparing coactivator recruitment levels in the 
presence of both PI and subsaturating concentration of GW7647 with levels acheived with GW7647 only. 
Data is plotted as % inhibition versus PI concentration. Data points represent the average of experiments 
performed in triplicate with the error bars representing the standard deviation. 
 
Antagonist effects of PIs outside of the PPAR receptor family were limited. 
Nelfinavir was found to interfere with LXRα coactivator recruitment in a dose-dependent 
manner achieving an inhibition plateau well below maximal inhibition, similar to results 
observed with nefinavir and other receptors (Figure 8). HIV PIs were found to have 
minimal effect on the remaining receptor panel with antagonist effects, if any, being 
observed only at highest drug concentrations.    
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Figure 8. Inhibition of LXRα Coactivator Recruitment by Nelfinavir. Nelfinavir was evaluated for 
inhibition of LXRα activation and coactivator recruitment in the antagonist mode coactivator recruitment 
assay. % Inhibition values were obtained by comparing coactivator recruitment levels in the presence of 
both PI and subsaturating concentration of 24(S)-hydroxycholesterol with levels acheived with 24(S)-
hydroxycholesterol only. Data is plotted as % inhibition versus nelfinavir concentration. Data points 
represent the average of experiments performed in triplicate with the error bars representing the standard 
deviation. 
 
2.3.2 Reporter Gene Assay 
Reporter assay – HIV drug panel and ligands 
The Gal4 reporter gene assay is a cell-based assay that measures receptor 
activation as a function of reporter gene transcription levels. Like the coactivator 
recruitment assay, the cell-based assay relies on coactivator recruitment by a receptor but 
also requires successful entry of the compound into the cell and coordinated assembly of 
transcriptional cofactors and enzymes.  EC50 values were obtained for each receptor and 
it’s ligand in the panel to ensure proper evaluation of HIV drugs in the antagonist assay 
and to provide validity to our assay methods. The EC50 values and associated ligands are 
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listed in Table 5. The EC50 values were calculated by fitting luminescence data to 
equation 1. The EC50 values were found to be within 3 fold of reported EC50 values in 
literature references listed in Table 5. 
HIV compounds were evaluated for induction of reporter gene transcription 
through agonist interactions with each member of the receptor panel. The efficacy of 
compounds, as indicated by % control, was determined by comparing reporter gene 
transcription levels to those achieved with saturating concentrations of receptor specific 
ligand. HIV compounds were considered to have an agonist effect if there was at least a 
30 % increase in signal over background. None of the HIV drugs tested showed any 
significant agonist activity in the reporter gene assay, confirming results obtained in the 
coactivator recruitment assay. The potent agonist effects of nelfinavir on FXR were not 
observed in the reporter assay.  The apparent lack of agonist activity was surprising since 
nelfinavir appeared to be a potent agonist in the coactivator recruitment assay. 
In the reporter assay, PXR was found to be activated by all PIs in the drug panel 
with the exception of indinavir (Figure 9). Ritonavir exhibited a full agonist titration in 
the range of concentrations tested and induced reporter gene transcription levels 
comparable to rifampicin. Ritonavir was calculated to have an EC50 of 2.6 ±0.4 μM 
approximating both the efficacy and potency of rifampicin, as previously reported [185]. 
Nelfinavir and saquinavir both activate PXR in a dose-dependent manner but lack a 
complete titration range within the concentrations tested. Nelfinavir exhibited a dose 
dependent response up to 2.5 μM, with decresing response at higher concentrations. EC50 
values for nelfinavir and saquinavir were 5.1 μM ± 1.3 and 31.8 μM ± 13.3, respectively. 
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The NRTI and NNRTI compounds were found to have no effect on transcription levels of 
the reporter gene regardless of the receptor tested. 
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Figure 9. Activation of PXR by PIs. Cells transfected with plasmids containing full length PXR and 
cyp3A4 RE-luc plasmids were incubated with either rifampicin, saquinavir, ritonavir or nelfinavir for 24 hr. 
Luminescence generated from expression of the luciferase reporter gene were compared to levels obtained 
under saturating concentrations of rifampicin. Data points outlined in black were excluded from equations 
used to generate EC50 values and data fitting. Data are plotted as % control versus compound concentration. 
With the exception of rifampicin, data represents the average of at least two determinations and the error 
bars are the standard deviation. 
 
Reporter assay – PI toxicity and receptor antagonism 
Compounds that interfere with ligand-induced receptor activation reduce levels of 
reporter gene expression. Any decrease in reporter gene transcription, however, can also 
result from a decrease in protein expression due to compound toxicity. PIs were evaluated 
for effects on HEK293 pG5luc+neo cell viability and caspase induction. Saquinavir, 
nelfinavir and ritonavir were found to affect cell viability at concentrations > 12.5 μM 
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while indinavir had no effect at the concentrations tested. However, increased levels of 
caspase expression were found at much lower PI concentrations than those found to have 
an immediate impact on cell viability. The results indicate that PIs trigger induction of 
the apoptotic pathway which can have generalized effects on rates of transcription and 
protein synthesis [231]. Therefore, only PI concentrations below induction of caspases 
could be used reliably for assessment of receptor antagonism. Caspase induction was 
considered significant if caspase levels were found to be > 1.7 fold over the vehicle 
control or > 10 standard standard deviations from baseline values (Figure 10 inset). The 
highest PI concentrations that could be reliably evaluated for antagonist activity were 
determined to be ≤ 15 μM for ritonavir and saquinavir and ≤ 1.2 μM for nelfinavir. PI 
receptor antagonism at these concentrations was considered significant if the % inhibition 
value exceeded 3 standard deviations. Ritonavir and saquinavir met this criterion for both 
PPARα and PPARγ (Table 8). 
 
Table 8. % Inhibition of PPARα and PPARγ Activation in the Cell-Based Reporter Gene Assay. 
 Ritonavir Saquinavir 
PPARα 52 % ± 8 34 % ± 11 
PPARγ 64 % ± 12 45 %  ± 8 
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Figure 10. Effect of PIs on Cell Viability and Caspase Induction in HEK293 Cell Line. HEK293 cells 
were incubated with PIs at various concentrations for 24 hr. Impact of PIs on both cell viability and caspase 
induction was determined by comparing ATP and caspase levels in control cells exposed to 0.1% DMSO 
only (vehicle control). Data is plotted as either % cell viability or fold caspase induction versus the 
concentration of PI. Data is the average of triplicate determinations and the error bars represent the standard 
deviation. 
 
2.3.3 Gene Expression Analysis 
Saquinavir and ritonavir effects on primary hepatocyte gene expression 
An exploratory study was performed to determine if gene expression levels in 
primary human hepatocytes were affected after a 24 hour exposure to media containing 
ritonavir or saquinavir. Genes with p-values ≤ 0.05 were selected and sorted by treatment 
group for up-regulated and down-regulated expression compared to the vehicle treatment 
group. Searches were performed within the treatment groups for genes previously 
reported to be regulated by PXR, SREBP, PPARα and PPARγ.  
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Several well characterized PXR target genes were up-regulated by both saquinavir 
and ritonavir treatments (Table 9). The data set was significantly enriched for genes of 
both phase I and phase II drug metabolizing enzymes, specifically cyp3A4, cyp2C9 and 
GSTT2. Interestingly, treatment of hepatocytes with saquinavir increased expression of 
the lipogenic enzyme, stearoyl CoA desaturase (SCD). SCD transcriptional regulation has 
recently been associated with the direct activation of PXR [187]. These results confirm 
that PXR activation in the presence of ritonavir and saquinavir observed in the cell-based 
reporter assay equates with induction of known PXR target genes in primary hepatocytes 
providing validation of our experimental design and methods.
ACCN# Gene Ritonavir Saquinavir 
PHASE I    
NM_022820 cytochrome P450, family 3, subfamily A, polypeptide 43 (CYP3A43)  2.4*   2.5** 
NM_000500 cytochrome P450, family 21, subfamily A, polypeptide 2 (CYP21A2) 3.3 6.4* 
NM_000896 cytochrome P450, family 4, subfamily F, polypeptide 3 (CYP4F3) 2.0        3.1* 
NM_000783 cytochrome P450, family 26, subfamily A, polypeptide 1 (CYP26A1) 1.8      -1.6* 
NM_000771 cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) 10.2*     11.5 
NM_017460 cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) 8.8*       8.1 
NM_000767 cytochrome P450, family 2, subfamily B, polypeptide 6 (CYP2B6)   3.0**       1.7 
NM_030622 cytochrome P450, family 2, subfamily S, polypeptide 1 (CYP2S1) 2.6*      -1.3 
NM_000777 cytochrome P450, family 3, subfamily A, polypeptide 5 (CYP3A5)  2.5**       2.3 
     
PHASE II    
NM_006588 sulfotransferase family, cytosolic, 1C, member 2 (SULT1C2)   -2.0**       -1.6 
NM_000854 glutathione S-transferase theta 2 (GSTT2)  23.3**  28.5** 
NM_000852 glutathione S-transferase pi (GSTP1)       4.3    7.2** 
NM_019093 UDP glucuronosyltransferase 1 family, polypeptide A3 (UGT1A3)       1.6  2.0* 
NM_053039 UDP glucuronosyltransferase 2 family, polypeptide B28 (UGT2B28) -1.4* -2.0* 
     
PHASE III    
NM_033226 ATP-binding cassette, sub-family C (CFTR/MRP), member 12 (ABCC12) 4.5* 3.4 
     
Lipogenic    
NM_005063 stearoyl-CoA desaturase (delta-9-desaturase) (SCD) 1.2 1.9* 
 
* Indicates p value < 0.05, ** < 0.01, all values reported for completeness 
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Table 9. Effect of Ritonavir and Saquinavir Treatment on the Expression Level of Known PXR Target Genes. 
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Prior evidence suggests that at least some of the dysfunction of cholesterol and 
fatty acid regulation found in HADL is due to HIV PI inhibited degradation of nuclear 
SREBP [88]. Comparison of published results of gene expression profiles obtained in 
transgenic mice over expressing SREBP isoforms with our data identified several 
overlapping genes [227]. Increased expression levels of genes involved in both fatty acid 
and cholesterol synthesis pathways were identified in both treatment groups (Table 10). 
The most significant changes were observed in the saquinavir treatment group with 
respect to both statistical merit and magnitude of change. The only gene found to be 
significantly increased by both treatment groups was SPOT14. With the exception of 
fatty acid desaturase (FADS) and SPOT14, modest increases in SREBP target genes were 
observed, ranging from 1.3 to 2.5 fold. These increases are similar to those obtained in 
studies using normal mice treated with ritonavir [88]. SCD was included in both the 
SREBP and PXR gene list due to overlapping control of SCD expression by these 
transcription factors [87, 187]. 
 
ACCN# Gene Ritonavir Saquinavir
    
 Fatty Acid Synthesis   
AI659296 acetyl-Coenzyme A carboxylase alpha γ   1.5*     2.0** 
NM_018677 acetyl-Coenzyme A synthetase 2 (ADP forming) (ACAS2), transcript variant 1 1.0, 1.2 1.5*, 1.6* 
NM_005063 stearoyl-CoA desaturase (delta-9-desaturase) (SCD) γ 1.2   1.9* 
NM_013402 fatty acid desaturase 1 (FADS1) delta-5-desaturase 1.4   5.6* 
NM_020918 glycerol-3-phosphate acyltransferase, mitochondrial (GPAM)   2.5*       1.2 
NM_004092 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial (ECHS1), nuclear gene 
encoding mitochondrial protein γ     1.0       1.5** 
NM_004104 fatty acid synthase (FASN) γ 1.3   1.8* 
NM_003251 thyroid hormone responsive (SPOT14 homolog, rat) (THRSP)  3.5*     2.7** 
 Cholesterol Synthesis   
NM_001096 ATP citrate lyase (ACLY), transcript variant 1 γ 1.2     1.3** 
NM_004458 acyl-CoA synthetase long-chain family member 4 (ACSL4), transcript variant 1 γ      1.2*       1.3* 
NM_004508 isopentenyl-diphosphate delta isomerase (IDI1) 1.2 1.4* 
NM_005891 acetyl-Coenzyme A acetyltransferase 2 (acetoacetyl Coenzyme A thiolase) (ACAT2)      1.7   2.3* 
BU741861 2,3-oxidosqualene:lanosterol cyclase 1.1 1.6* 
 Miscellaneous   
NM_014573 hypothetical protein MAC30 (MAC30)  1.3*      1.3 
NM_018645 hairy and enhancer of split 6 (Drosophila) (HES6)   1.5*      1.1 
NM_001169 aquaporin 8 (AQP8) 1.2 1.9* 
* indicates p value <0.05, ** <0.01, all values reported for completeness 
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In general, PPARγ target genes identified in the data sets were down regulated by 
both saquinavir and ritonavir treatments supporting observations of inhibition of PPARγ 
activation in both the coactivator and cell-based transcription assays (Table 11). The 
PPARγ gene set contains down regulated genes of various activity within biological 
processes rather than enrichment of any particular pathway. GLUT2 and glucokinase 
(GK), major mediators of glucose uptake and metabolism, were down regulated with 
significant reduction of glucokinase observed in both treatment groups. Reduction in 
expression levels > 2 fold were also observed for the fatty acid metabolism enzymes 
glycerol-3-phosphate dehydrogenase (GPD) and mitochondrial 3,2 trans-enoyl-CoA as 
well as insulin-like growth factor-1 (IGF-1) and promethin. No PPARα target genes, 
meeting statistical criteria, were found in the microarray data set.  
78 
ACCN# Gene Ritonavir Saquinavir
      
NM_000340 solute carrier family 2 (facilitated glucose transporter), member 2 (SLC2A2) -2.0* -1.2 
NM_033507 glucokinase (hexokinase 4, maturity onset diabetes of the young 2) (GCK)   -2.9**    -4.6** 
NM_000041 apolipoprotein E (APOE) -1.2* 1.0 
NM_002970 spermidine/spermine N1-acetyltransferase 1 (SAT1)    1.2**     1.6** 
NM_005693 nuclear receptor subfamily 1, group H, member 3 (NR1H3), LXRα -1.5** -1.2 
NM_005276 glycerol-3-phosphate dehydrogenase 1 (soluble) (GPD1) -2.0* -1.6* 
NM_032564 diacylglycerol O-acyltransferase (DGAT2) -1.5* 1.0 
BF002257 phospholipid transfer protein (PLTP precursor) -1.7* -1.2* 
NM_020672 S100 calcium binding protein A14 (S100A14)   -1.5** 1.1 
NM_018441 peroxisomal trans-2-enoyl-CoA reductase (PECR)  -1.4** 1.0 
NM_000618 insulin-like growth factor 1 (somatomedin C) (IGF1) -1.6**,-2.3* -1.1,-3.4*
NM_004092 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial (ECHS1) 1.0    1.5** 
NM_021814 ELOVL family member 5, elongation of long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3-like, yeast) (ELOVL5) 
-1.3* 1.0 
NM_021213 phosphatidylcholine transfer protein (PCTP) 1.3 1.5* 
AA581670 mitochondrial 3,2 trans-enoyl-CoA isomerase       -2.1**     -1.6* 
NM_020422 transmembrane protein 159 (Promethin)        -2.0     -4.7* 
       * indicates p value <0.05, ** <0.01, all value reported for completeness 
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 † p-values based on DMSO 
 ‡ p-values based on troglitazone 
 indicates p-value * <0.05, **<0.01 
r
GLUT2 arra
qRT-PCR experiments confirmed treatment effects on expression levels of GK 
and GLUT2 in primary hepatocytes (Table 12). Troglitazone, a PPARγ specific agonist, 
also increased the transcription of GLUT2. A slight increase in GK was observed but did 
not reach statistical significance. Incubation of troglitazone in combination with the PIs 
overcame the decrease of both GK and GLUT2 mRNA when compared to treatment with 
saquinavir and ritonavir alone. 
Table 12. qRT-PCR Analysis of GK and GLUT2 Expression in Primary Human Hepatocytes. 
Saquinavir and ritonavir effects on GK and GLUT2 expression in primary hepatocytes 
GK arra
 
itonavir saquinavir troglitazone
y† -2.0* -1.2 -
qRT-PCR† -2.6* 1.0  2.3* 
qRT-PCR + troglitazone‡   1.5**  1.5* -
y†  -2.9**  -4.6** -
-2.1qRT-PCR† * -5.5* 1.4
qRT-PCR + troglitazone‡  -1.5** -1.4** -
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2.4 Discussion 
The use of HAART in the treatment of HIV infection has resulted in a dramatic 
decline in AIDS-related deaths [2-4]. However, it is widely recognized that HAART, 
especially those containing the PI class of antiretroviral drugs, is also associated with a 
variety of metabolic side effects. These side effects include hypertriglyceridemia, insulin 
resistance, hypercholesteremia and body fat redistribution, collectively known as HADL 
[20, 21]. The cause of HADL appears to be multifactorial, involving the disruption of 
multiple pathways, which have only complicated a detailed understanding of the 
mechanisms involved. Despite many advances in unraveling the complex events and 
pathway perturbations involved in the development of HADL, a complete understanding 
of the biological processes involved for the totality of symptoms observed in the clinical 
definition of the syndrome, as well as, mechanistic difference between members of the PI 
class, have yet to be fully defined.   
The goal of this project was to investigate the role of nuclear receptor activation 
in the development of HADL, with a specific interest in receptors whose target genes 
reside in pathways that regulate energy storage and metabolism. The panel of HIV drugs 
listed in Table 2 was evaluated for effects on nuclear receptor activation using both cell-
free and cell-based methods measuring coactivator binding and reporter gene 
transcription.  
Coactivator recruitment results indicated that nelfinavir was a full and potent 
activator of FXR. The potency of nelfinavir activation was dependent on the coactivator 
peptide recruited by FXR in the order of potency bSRC-1 M2 > bPGC-1 > bCBP. 
However, this robust activation could not be confirmed in the cell-based reporter assay. 
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Failure to reproduce the activity of a potent FXR agonist in cell-based systems has been 
reported previously and was attributed to issues concerning compound solubility [232]. 
Intrinsic FXR activators, such as bile acids, are derived from cholesterol and, therefore, 
hydrophobic in nature. Exogenous compounds that activate FXR must retain the chemical 
characteristics of the intrinsic ligand in order to form positive interactions with amino 
acids in the ligand binding pocket. Studies using various pharmaceutical formulations of 
nelfinavir report a maximum solubility of ~10 μM in aqueous solutions, with higher 
concentrations attainable in solutions containing DMSO [233]. Therefore, solubility of 
nelfinavir could not have been a factor in the cell-based assay since a measurable 
transcriptional response should have been possible with concentrations < 10 μM. In 
addition, nelfinavir has been shown to rapidly accumulate in cultured cells with 
concentrations greater than 30-fold over media concentrations having been reported 
[234]. This suggests that neither solubility nor inadequate intracellular accumulation 
provide an explanation for the lack of transcriptional response. The coactivator 
recruitment results were scrutinized for any indication of assay interference which could 
have been interpreted as potent activation of FXR. Values from the raw fluorescence 
readings did not indicate interference in absorption or emission readings. Fluorescence 
interference by nelfinavir is highly unlikely due to the time resolved nature of 
fluorescence energy transfer of europium. In addition, general assay interference by 
nelfinavir would have been observed in other receptor assays since the assay components, 
including GST-tag and inclusion of bSRC-1, were common to other receptors in the 
panel.  
  82 
The reason for the apparent discrepancy in nelfinavir effects may lie in the nature 
of the assays. The methods used to evaluate drug effects on nuclear receptor activation 
may not accurately represent the in vivo requirements for efficient gene transcription. 
Coactivator assembly by an activated receptor entails the recruitment of a primary 
coactivator, binding directly to the AF-2 region, through which the remaining coactivator 
complex is anchored [126]. The coactivator complex is comprised of many coactivator 
proteins with diverse roles in facilitating recruitment of transcriptional machinery such as 
chromatin remodeling, DNA unwinding and interaction with general transcription factors 
[125].  The composition of the coactivator complex and the order of recruitment are 
influenced by many factors. Cell-type coactivator abundance, as well as, agonist and 
response element binding effects on LBD conformation all influence the order of 
complex assembly, composition of the complex and ultimately the level of transcriptional 
response [136-138]. In this instance, use of the Gal4 system, rather than a system relying 
on direct binding of FXR to target gene RE sequences may have prevented an efficient 
transcriptional response. Experiments utilizing full length FXR and RE sequences from 
different target genes or quantitation of protein levels of target genes, such as the bile salt 
export pump (BSEP) and short heterodimer partner (SHP), in relevant cell lines need to 
be performed in order to determine the potential for in vivo activation of FXR by 
nelfinavir [171, 173]. 
Analysis of inhibitor effects on nuclear receptor activation in the coactivator assay 
indicated that micromolar concentrations of ritonavir, saquinavir and nelfinavir prevent 
ligand-induced activation of PPARα and PPARγ. Nelfinavir was shown to inhibit the 
activation of LXR but to a lesser extent than effects observed for PPARα/γ. Unlike the 
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other PPAR family members, PPARδ activation was unaffected by HIV PIs. This result 
was not surprising since ligands that activate both PPARα/γ often have little to no effect 
on the activation of PPARδ [224]. While the sequence homology between the LBDs of 
the PPAR family members is 60-70 %, the ligand binding pockets of PPARα and PPARγ 
are spatially much larger than PPARδ [235]. Minor differences in the amino acid 
sequence surrounding the binding pocket of PPARδ cause a narrowing of the LBD close 
to the AF-2  helix [235]. This excludes the productive binding of many large and potent 
ligands of the PPARα/γ subtypes, such as thiazolidinones (TZDs) and fibrates [235]. The 
narrow binding pocket of PPARδ together with the large structures of PIs provides a 
reasonable explanation for the subtype specific effects of PIs within the PPAR family. 
Direct measurement of PI effects on receptor activation in the cell-based reporter 
gene assay proved problematic. All PIs, with the exception of indinavir, were found to 
decrease cell viability at concentrations exceeding 12.5 μM. Others have reported similar 
effects on the viability of B and T-cell lines at concentrations greater than 10 μM and 
caution the interpretation of PI-mediated cellular effects under such conditions [90, 236]. 
However, the cellular toxicity of PIs at these concentrations do highlight the global 
effects these drugs have on normal cellular function and are responsible, in part, for the 
development of acute side effects, such as hepatotoxicity and gastrointestinal 
disturbances [237] Lower concentrations, while not impacting cell viability directly, were 
found to induce expression of caspases, indicating induction of apoptotic pathways and 
the possibility of negative effects on cellular rates of transcription and translation [231]. 
Transcriptional effects at PI concentrations low enough to avoid caspase induction, 
confirmed the inhibition of PPARα/γ activation by saquinavir and ritonavir observed in 
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the coactivator recruitment assay. However, we were unable to confirm the inhibitory 
effects of nelfinavir due to significant toxicity at concentrations that would have been 
required for inhibition of both LXR and PPARα/γ activation.  
Therapeutic drug monitoring studies indicate that maximal plasma concentrations 
(Cmax) of ritonavir, under recommended doses, are in the range of 15 μM [93]. 
Saquinavir, administered as a monotherapy, has a reported Cmax of 300 nM. However, 
current guidelines require coadmistration of saquinavir with small doses of ritonavir in 
order to ‘boost’ saquinavir exposure, resulting in an improved Cmax of ~10 μM [92, 238]. 
Based on the pharmacokinetic data of PIs, inhibition of PPARα/γ activation by ritonavir 
and saquinavir at micromolar concentrations is possible under current dosing guidelines.  
Microarray analysis was performed on mRNA transcripts from primary human 
hepatocytes to determine whether partial inhibition of PPARα/γ activation would be 
significant enough for measurable effects on the abundance of known target genes. 
Changes in PXR target genes abundance, as well as those of SREBP, were also 
evaluated. We expected that PXR activation by saquinavir and ritonavir in the reporter 
gene assay would result in increased expression of genes involved in drug metabolism 
pathways in hepatocytes. Even though SREBP was not included in our initial 
experimental design, evaluation of changes in target gene expression was included due to 
expected effects on SREBP target gene transcription with ritonavir and saquinavir and the 
overlap of transcriptional control of lipogenic pathways with PPAR and PXR. 
Microarray analysis of differentially expressed genes in primary human 
hepatocytes with either ritonavir or saquinavir treatment demonstrated robust induction of 
drug metabolizing enzymes consistent with transcriptional activation of PXR in the 
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reporter gene assay. Activation of PXR by the PI class of HIV drugs has been described 
previously [185]. A recent publication examining changes in liver gene expression 
profiles among different PIs, failed to show changes in transcriptional response indicative 
of PXR activation. The microarray data obtained in these experiments were derived from 
transcriptional responses in the HepG2 cell line. Wilkening et al. compared the drug 
metabolizing capabilities of primary hepatocytes and HepG2 cells and demonstrated that 
HepG2 cells do not retain drug metabolizing characteristics of the primary cell line [239]. 
The expression of all p450 enzymes was found to be 100 to 1000 fold less when 
compared to primary hepatocytes. In addition, Jover et al. found that liver-specific 
transcription factors such as, hepatocyte nuclear factors and C/EBPα, are also expressed 
at lower levels in HepG2 [240]. In contrast, primary human hepatocytes have been shown 
to be equally effective as liver slices in their ability to reproduce drug effects on gene 
expression profiles observed in vivo [241]. The absence of crucial drug metabolizing 
capabilities, as well as transcription factors and cofactors, requires that claims based on 
gene effects in the HepG2 cell line be considered with caution.  
Recent studies indicate that PXR activation has the potential to induce lipogenic 
pathways through mechanisms independent of SREBP activation [187]. PXR mediated 
hepatic lipid accumulation correlated with increased expression of SCD-1, fatty acid 
elongase (FAE) and FAT/CD36 as well as suppression of β-oxidation pathways. The 
implications of PI-mediated PXR activation on lipid and fatty acid synthesis are 
unknown. While we were unable to identify the majority of lipogenic genes currently 
linked to PXR activation, SCD-1 was found to be up regulated in response to saquinavir 
treatment. Increased expression and activity of SCD-1 has been linked to the onset of 
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diet-induced hepatic insulin resistance [242]. Whether this increased expression is a 
direct result of PXR activation remains uncertain since transcriptional control of SCD-1 
overlaps with SREBP [87, 187]. Since PIs have been shown to prevent degradation of 
SREBP directly, SREBP KO models would be required to determine PXR specific 
effects on SCD-1 expression. In addition, experiments employing an extended time 
course of treatment and transcriptional analysis would provide an opportunity to capture 
transcriptional changes in other PXR lipogenic genes currently absent from our data set. 
Although hepatic steatosis in PI treatments has been linked to uncontrolled transcription 
of SREBP target genes, activation via PXR could provide an additive effect in saquinavir 
based therapies. 
Consistent with increased accumulation of nSREBP due to proteasome inhibition, 
several genes implicated in SREBP-mediated lipogenic pathways were up regulated in 
response to both ritonavir and saquinavir treatments. Increased expression of ATP-citrate 
lyase and acetyl-CoA synthetase indicate cellular conditions favorable for production of 
acetyl-CoA, an essential precursor for both monounsaturated fatty acid and cholesterol 
biosynthetic pathways. A significant increase of SPOT14 expression was observed in 
both treatment groups. While expression of SPOT14 has been directly correlated with 
SREBP activity, the function of SPOT14 in lipogenic processes is unknown. The 
development of SPOT14 KO models suggest that SPOT14 may function as a transporter 
of fatty acids [243]. SPOT14 KOs have been shown to accumulate malonyl-CoA, the 
product of acetyl-CoA carboxylase and the substrate of FAS. It is hypothesized that 
SPOT14 serves to eliminate product inhibition of FAS through transport of fatty acids, 
promoting a favorable environment for fatty acid accumulation.  
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The microarray gene set did not contain PPARα target genes meeting statistical 
significance. Due to the low number of samples submitted for microarray analysis, a 
relatively small number of genes meet criteria for statistical significance. The limited 
sample set certainly resulted in exclusion of differentially expressed genes due to 
statistical failure. For this reason, many SREBP and PXR target genes, whose expression 
levels were described to be affected by PI treatment, such as the drug export pump, 
MDR1 and HMGCoA synthase, were excluded from the data set [88, 244]. Failure to 
achieve statistical significance combined with the modest inhibitory effects predicted 
from the reporter assay may provide an explanation for the absence of differentially 
expressed PPARα target genes. In order to rule out inhibition of PPARα activation as a 
potential mechanism towards development of HADL, additional experiments, consisting 
of greater replicates, as well as, time course evaluation of transcriptional change, need to 
be conducted. 
 In contrast to PPARα, several PPARγ target genes were identified in the 
microarray gene set in both treatment groups. In general, expression levels of these target 
genes were decreased by both ritonavir and saquinavir treatment, consistent with 
inhibitory effects on receptor activation in both the coactivator and reporter gene assays. 
Target gene assignment was based on both experimental and bioinformatic evidence 
suggesting that PPARγ was responsible, in part, for modulation of transcript abundance 
[146, 226, 245]. However, transcriptional control for many of these genes overlap with 
other transcription factors such as LXRα, PPARα and SREBP, providing a monumental 
hurdle in establishing a direct relationship between the state of PPARγ activation and 
gene expression [246, 247] . Several fatty acid and cholesterol biosynthetic genes listed 
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in the SREBP target gene table (γ notation) are also controlled by PPARγ [226, 227]. 
Cross talk between nuclear factors in the regulation of fatty acid and cholesterol 
pathways, especially those shared with SREBP, prevented general conclusion from being 
made pertaining to the effects of PI-mediated inhibition of PPARγ activation within the 
context of the microarray experimental methods.  
However, qRT-PCR results indicate that negative effects on GK and GLUT2 gene 
expression by ritonavir and saquinavir treatments may occur through direct inhibition of 
PPARγ activation. This conclusion is based on the observation that treatment of 
hepatocytes with troglitazone in combination with either ritonavir or saquinavir results in 
partial reversal of inhibitory effects on GK and GLUT2 expression levels when compared 
to ritonavir/saquinavir treatment groups. Supporting this observation, Goetzman et al. 
also noted partial inhibition of rosiglitazone–induced expression of the PPARγ target 
genes, PEPCK and UCP-2, in the adipose tissue of mice when rosiglitazone was 
coadministered with ritonavir [248].  In addition, troglitazone treatment of hepatocytes 
resulted in a 2 fold increased expression of GLUT2, indicating direct transcriptional 
control of this gene by ligand-activated PPARγ. These observations are consistent with 
previous reports of increased GLUT2 mRNA in hepatocytes treated with rosiglitazone as 
well as the identification of PPAR RE sequences in the +68/+89 and -197/-184 region of 
the rat and mouse GLUT2 promoters, respectively [155, 249].  While we were unable to 
establish a direct connection between GK and PPARγ activation due to statistical 
constraints, positive effects on GK transcription levels have been reported by others. 
Kliewer et al. reported increased levels of GK mRNA in the liver of diabetic ZDF rats 
treated with the PPARγ-specific agonist GW1929. Kim et al. reported similar effects on 
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GK expression in rat hepatocytes treated with troglitazone [154]. This group also 
identified a functional PPAR RE sequence in the -116/-104 region of the rat GK gene 
suitable for direct binding of PPARγ/RXRα heterodimers.  
Identification of several cis and trans-activating sites within the GLUT2 promoter 
region indicate the interplay of multiple transcription factors in tissue-specific gene 
regulation [250]. Hepatocyte nuclear factor-6 (HNF6) influences the expression levels of 
both GK and GLUT2 in pancreatic β-cells [251]. Inactivation of the HNF6 gene was 
associated with a 50 % decrease of GK mRNA compared to controls, confirming 
compensatory mechanisms and overlap of transcriptional control [252]. Other 
transcription factors, such as the PDX-1 homeobox factor and SREBP-1c, have also been 
implicated in the transcriptional control of GLUT2 and GK, respectively [253]. 
Therefore, the possibility that transcriptional repression is occurring through PPARγ-
independent mechanisms, which are overcome by increasing transcription via 
troglitazone-activated PPARγ, can not be ruled out. 
GLUT2 and GK play an important role in GSIS and the postprandial processing 
of glucose and are expressed in the liver, as well as pancreatic β-cells [254-256]. GLUT2 
and GK are low affinity binders of glucose and provide liver and β-cells with increased 
sensitivity to high levels of circulating glucose. The Km of most glucose transporters are 
between 2 - 5 mM [256]. GLUT2, however, has a high transport capacity and a higher Km 
for glucose (> 6 mM) and is better suited to decrease high levels of circulating glucose 
after feeding  [257]. When blood glucose levels exceed 5.5 mM, glucose is transported by 
GLUT2 into cells where it is rapidly phosphorylated to glucose-6-phosphate (G-6-P) by 
hexokinases, trapping glucose within the cell. GK, also known as hexokinase 4, is one of 
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four hexokinases found in humans [254] . Like GLUT2, GK also has a low affinity for 
glucose (Km 6-15 mM) and is the primary hexokinase involved in G-6-P formation under 
high glucose conditions [254]. GK has an additional advantage over other hexokinases in 
that it is not subject to product inhibition by physiological concentrations of G-6-P 
ensuring sustained processing of glucose. GK activity is the rate-limiting step for glucose 
metabolism in both β-cells and liver. The concerted actions of GLUT2 and GK result in 
the intracellular accumulation of G-6-P which facilitates fatty acid synthesis and 
glycogen storage in the liver and insulin secretion in β-cells. Proper function of GLUT2 
and GK are essential for reduction of circulating glucose levels through induction of 
insulin-mediated peripheral cellular uptake and glycogen storage in the liver [258].  
 Loss of function mutations of GK have been identified in families with maturity 
onset diabetes of the young (MODY2) [259]. MODY2 mutations are located throughout 
the GK gene and produce GKs with lower kinetic rates in the formation of G-6-P. 
Decreased rates in the formation of G-6-P delay insulin secretion, as well as hepatic 
glycogen synthesis, in response to high glucose levels, highlighting the importance of GK 
in the maintenance of glucose homeostasis [260]. Reduced levels of liver GK activity 
have also been reported in diabetic patients negative for MODY2 [261-263]. Hepatocytes 
isolated from diabetic Zucker rats were found to have 4.5 fold less GK activity compared 
to normal rats [264]. Transgenic models have demonstrated that relatively modest 
increases in liver GK expression levels can lead to substantial changes in blood glucose 
concentrations [264, 265]. Increasing liver GK activity by 20 % in transgenic mice was 
shown to improve glucose tolerance, insulin secretion and reduce body weight [266]. 
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Small molecule GK activators are currently being investigated as potential therapies in 
the treatment of diabetes [267, 268]. 
While the role of GK in the pathogenesis of diabetes has been firmly established, 
the role of GLUT2 is less certain. Reduction of β-cell GLUT2 transcripts have been 
observed in many rodent models of diabetes [269]. However, comparison of human and 
rodent GLUT2 mRNA in β-cells indicate that GLUT1 may be the primary glucose 
transporter for humans at this site and has brought into question the relevance of GLUT2 
in the manifestation of diabetes in humans [270, 271]. Despite these observations, there is 
direct evidence supporting a role for GLUT2 in the dysfunction of glucose uptake and 
GSIS. In diabetic islets from human cadavers, mRNA expression of GLUT1, GLUT2 and 
glucokinase was reduced by 20, 50 and 30 %, respectively [272]. The reduction of GK 
and GLUT2 expression, not GLUT1, was found to correlate directly with a 50 % 
reduction of glucose oxidation in the islets. Mutations of liver GLUT2 found in Fanconi-
Bickel syndrome, a rare autosomal recessive disorder of glucose metabolism, results in 
fasting hypoglycemia and postprandial glucose intolerance [273]. In addition, 
polymorphisms in the promoter region of the GLUT2 gene have been associated with an 
increased risk of developing type 2 diabetes through decreased expression of GLUT2 
[274]. 
HIV patients receiving PI-containing therapies often display impairments in 
glucose processing and β-cell function. PIs, especially indinavir, have been shown to 
interfere with peripheral glucose uptake through direct binding of GLUT4. Other GLUT 
isoforms are also targets of PI inhibition but to a lesser extent than GLUT4. Suppression 
of glucose stimulated insulin release has also been observed in mouse pancreatic islets 
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and MIN6 cells [275]. Indinavir treatment reduced insulin release by 50 % at 
concentrations > 2 μM. Indinavir was shown to have no effect on GK activity at these 
concentrations, suggesting glucose signaling was being blocked at the transport level. 
Similar observations were made with ritonavir and saquinavir treatment but at 
concentrations 10 fold higher than those required for inhibition with indinavir. The 
concentrations of saquinavir/ritonavir required for GLUT4 inhibition are above Cmax 
values and, therefore, may not be relevant in vivo. Unfortunately, GK activity levels were 
not determined for these PIs. A single dose of 1200 mg indinavir administered to healthy 
volunteers was found to increase insulin resistance by 35 %, supporting the rapid effects 
of indinavir on peripheral glucose transport [276]. Similar studies with ritonavir showed 
no significant change in insulin resistance, confirming differences in glucose processing 
between indinavir and other PIs [277]. However, long-term administration of ritonavir 
did cause significant changes in glucose tolerance upon administration of the oral glucose 
tolerance test. These findings suggest that individual PIs may have differential effects on 
glucose metabolism resulting in similar long term risks of developing diabetes.  
Differences between indinavir and other PIs were also observed in our evaluation 
of PI effects on metabolic nuclear receptors. Saquinavir and ritonavir both inhibited the 
activation of PPARα/γ while indinavir had no effect. Formulation studies of indinavir 
indicate that indinavir is soluble in aqueous solution up to ~25 μM, excluding solubility 
as a potential reason for the lack of indinavir effects [233]. Intracellular accumulation of 
indinavir is limited and often approximates concentrations in culture media [234]. In fact, 
cell lines engineered to overexpress MDR1, reduce indinavir concentrations below limits 
of detection. While active efflux of indinavir by MDR1 may explain the lack of cellular 
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toxicity at concentrations approaching 100 μM, lack of inhibitory effects on receptor 
activation in the cell-free coactivator recruitment assay are likely mechanistic. The 
differential effects observed in PPAR α/γ activation may provide insight into the 
metabolic differences between saquinavir/ritonavir and indinavir based therapies and 
deserves further investigation. 
Our research has confirmed that saquinavir/ritonavir based therapies influence the 
transcription of genes involved in drug metabolism through direct activation of PXR and 
suggest that induction of lipogenic processes are possible through PXR activation. 
Saquinavir and ritonavir also increased the expression of genes within cholesterol and 
fatty acid biosynthetic pathways providing further confirmation of PI lipogenic effects 
through nuclear accumulation of SREBP. Inhibitory effects were also observed in the 
activation of PPARα/γ, suggesting a role for metabolic nuclear receptors in the 
manifestation of HADL. Reduced expression and activity of GLUT2 and GK has been 
directly linked to development of diabetes and may contribute to insulin resistance and 
glucose intolerance in HIV patients receiving saquinavir/ritonavir based therapies, as 
well. TZDs have demonstrated some usefulness in the alleviation of HADL symptoms in 
HIV patients by decreasing insulin resistance, increasing subcutaneous body fat with 
modest effects on circulating triglycerides [278, 279] . These effects have been attributed 
primarily to improvements in subcutaneous adipose depots, increased efficiency in fatty 
acid uptake and favorable adipokine secretion at this site [205]. Our research has shown 
that positive effects on the expression of GK and GLUT2 in the liver and possibly 
pancreatic β-cells may also contribute to the positive effect of TZDs in treating HADL 
symptoms.  
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Chapter 3: Comparison of Full Length Versus Ligand Binding Domain 
Constructs in Cell Free and Cell Based PPARα Assays 
Publication: Jennifer Berbaum and Richard K. Harrison, Analytical Biochemistry, 
 339 (2005) 121-128. 
 
3.1 Introduction  
Peroxisome proliferator-activated receptor alpha (PPARα) is a ligand-induced 
transcription factor belonging to the super family of nuclear hormone receptors [280]. 
The PPAR family consists of three members, alpha, gamma and delta, all of which are 
involved in the regulation of genes that control glucose, lipid, and cholesterol metabolism 
[224, 281]. PPARα has been shown to play a direct role in lipid homeostasis through the 
regulation of PPARα responsive genes [280]. These genes contain peroxisome 
proliferator responsive elements (PPREs) within the promoter region of the gene, where 
the ligand-activated PPARα and its obligate heterodimer partner, retinoid X receptor, 
bind and modulate gene transcription through recruitment of transcriptional machinery 
[193]. Most genes found to contain PPREs are involved in lipid catabolism, transport and 
storage pathways [280, 282]. PPARα is known to be activated by a variety of compounds 
including fatty acids and the fibrate class of hypolipidemic drugs [283]. Because of its 
role in dietary lipid regulation, PPARα has become an attractive target for drug 
development [224]. The potential role of PPARα in diseases such as diabetes, obesity and 
atherosclerosis has resulted in a considerable effort towards developing methods to 
accurately evaluate effects of drugs on PPARα receptor activation and subsequent gene 
regulation [203, 284]. 
The assays developed to analyze both PPARα activation and gene transcription 
exploit the unique structure and function of nuclear receptors. All nuclear receptors 
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contain six functional domains [115]. The N-terminal A/B domain contains the ligand-
independent activation function (AF-1), which allows for constitutive expression of genes 
while the receptor is in an unliganded state. The C domain encodes the DNA binding 
domain (DBD) containing characteristic GC-rich regions and zinc finger motifs. The 
DBD interacts directly with receptor-specific gene response elements. The D domain, 
also known as the hinge region, connects the ligand binding domain (LBD) to the DBD. 
The hinge region is thought to play a role in transcriptional silencing and modulation of 
binding of the receptor to DNA. The E/F domain contains the LBD, a ligand-dependent 
activation function AF-2, dimerization sequences, and nuclear localization sequences. 
These distinct functional domains have allowed for development of cassettable systems 
for analyzing drug interaction with nuclear receptors [285].  
Historically, assays such as the Gal4 transactivation and coactivator recruitment 
assays have relied solely on the LBD of the receptor in order to determine potency and 
efficacy of potential PPARα agonists. Coactivator recruitment assays assess agonist 
potency through measurement of the receptors ability to recruit coactivator peptides [283, 
286]. Binding of the coactivator occurs due to conformational changes brought about by 
agonist binding [287]. The level of recruitment is measured through the transfer of energy 
between molecules such as allophycocyan (APC) and europium (Eu), which only occurs 
when the two are in close proximity [211]. Receptor constructs for these assays typically 
involve the use of GST, c-myc or His6 N-terminal tags for detection purposes and a 
truncated form of the receptor for agonist binding.  
The cell based Gal4 transactivation assay utilizes the 1-147 amino acid sequence 
of the yeast Gal4 transcription factor as a generic DBD [288]. The resulting chimera, 
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composed of an artificial DBD and native LBD, relies on the LBD for agonist binding 
and the Gal4 DBD for DNA binding. The chimera must be able to bind agonist and 
recruit transcriptional machinery in order for reporter gene expression to occur. The level 
of reporter gene induction indicates agonist efficacy on downstream gene transcription. 
This assay format is useful because it eliminates the need to generate specific response 
element reporter systems for each receptor to be investigated. However, like the 
coactivator recruitment assay, the Gal4 chimeras only include the LBD portion of the 
nuclear receptor. The reason for exclusion of full length nuclear receptors in these assay 
formats is unclear. Perhaps it is thought that inclusion of the native DBD in a Gal4 
system would decrease overall transcription of reporter gene because of binding of the 
DBD to native RE in the cell. A recent publication concerning estrogen receptor alpha 
suggests that there are differences in LBD and full length receptor conformations upon 
binding of the same ligand [289]. These conformational differences appear to influence 
the binding of coactivator peptides and consequently agonist efficacy [289]. 
To determine whether similar effects would be seen for PPARα, we examined the 
potency and efficacy of several well characterized PPARα agonists using full length and 
LBD constructs. The results from these assays lead to an increased understanding of the 
binding and efficacy results from nuclear receptor assays, and suggest subtitle differences 
in the binding of coactivators to full length and ligand binding domain constructs.  
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3.2 Materials and Methods 
The preceding methods have been described previously in Chapter 2 sections 
2.2.2 thru 2.2.4. The methods were included in order to maintain the integrity of the 
published work. 
 
Reagents 
All solvents and buffer components were purchased from Sigma unless otherwise 
noted. cDNA was purchased from Invitrogen corp. Cell culture media and reagents were 
purchased from both Mediatech and Invitrogen except for charcoal stripped fetal bovine 
serum, which was purchased from Hyclone. 
 The coactivator peptides bSRC-1 M2, bPGC-1 and bCBP were synthesized and 
prepared to 95 % purity by Synpep Corp (Table 1). Europium-labeled anti-GST antibody 
was purchased from CIS-Bio US Inc. Allophycocyan-labeled strepavidin was purchased 
from Perkin Elmer. GW7647 was purchased from Sigma. Bezafibrate, Ciprofibrate and 
WY 147647 were purchased from Biomol.  
 
Cloning and Expression of GST-PPARα FL and LBD constructs 
The full length (FL) and the ligand binding domain (LBD) (166-468 aa) of the 
human PPARα gene, Genbank accession # L02932, were amplified from kidney cDNA 
using the primers in (Table 3). PCR reactions were conducted using BD Clontech’s GC-2 
and HF-2 PCR polymerases. PCR products were gel purified and TOPO cloned into 
Invitrogen’s Gateway entry vector, pENTR / D-TOPO.  Single clones were selected 
based on their resistance to kanamycin and the isolated plasmids, pENTR: PPARα FL / 
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LBD, were sequenced to confirm complete gene insertion. The pENTR: PPARα FL / 
LBD plasmids were then recombined with the Gateway destination vector pDEST15 
using LR clonase as per manufacturer’s procedure. pDEST15 confers a C-terminal 
glutathione-S-transferase (GST) tag in-frame with PPARα FL / LBD receptor. Single 
colonies containing pDEST15: PPARα FL / LBD plasmids were selected based on 
resistance to carbenicillin. pDEST15: PPARα FL / LBD plasmids were then transformed 
into BL21 (DE3) pLysS for protein expression.  
Transformed 1 liter cultures were induced at an OD600 of 0.4 to 0.6 with fresh 0.4 
mM IPTG and grown at room temperature for 4 hours. Cells were harvested by 
centrifugation at 12,000g. Cell pellets were frozen at –20ºC and lysed by thawing on ice. 
50 ml of Buffer A containing 50 mM Tris pH 8.0, 50 mM KCl, 1 mM EDTA, 1 mM 
DTT, 10 % glycerol and 1 mM PMSF were added to the cell pellets. The cell aggregates 
were disrupted by passage through an 18-gauge syringe or homogenizer. 
Deoxyribonucease I (DNaseI ) was added to the lysate at a final concentration of 20 
μg/ml and incubated at 37 ºC for 2 hours. The cell lysate was clarified by centrifugation 
at 50,000g and filtered through a PES 0.22 μM filter prior to purification. Purification of 
the GST-receptor fusions was performed using Glutathione 4B resin (Amersham 
Biosciences). Column equilibration and washing were performed with Buffer A. Proteins 
were eluted from the column using Buffer A with the addition of 20 mM glutathione (pH 
8.0). Protein concentrations were determined by Bradford assay and the protein was 
<95% pure as visualized by SDS-PAGE and western blot. 
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Coactivator titrations 
Coactivator recruitment was determined by a homogenous time-resolved 
coactivator recruitment assay. Each coactivator assay contained 100 nM GST-PPARα FL 
or LBD, 100 nM  streptavidin-APC, 3 nM europium (Eu)-labeled anti-GST antibody and 
1 μM GW7647 / DMSO in assay buffer (50 mM Tris pH 8.0, 50 mM KCL, 1 mM 
EDTA, 1 mM DTT and 1 mg / ml BSA). All components were optimized for maximal 
assay signal. The coactivator peptides bSRC-1 M2, bPGC-1 and bCBP were diluted in 
dH2O to a final stock concentration of 1 mM. A 10 μL aliquot of various concentrations 
of coactivator were added to the complete assay mix (final assay volume 100 μl, 1 % 
DMSO) in 96-well black optiplates (Perkin Elmer).  Contents were mixed by pipetting, 
and the plates were spun at 300g for 1 minute to remove bubbles. Plates were covered 
and incubated for 2 hours at room temperature. Fluorescence was measured by excitation 
at 340 nm and reading of emission at 615 nm and 665 nm. Measurements were performed 
on the Perkin Elmer Fusion using the factory settings for time-resolved fluorescence. 
 
Agonist titrations 
 Agonist potency was determined using the same assay format as the 
coactivator titrations with one exception. Instead of varying coactivator concentration, the 
concentration of agonist was varied in the experiment. Each HTRF assay contained 100 
nM GST-PPARα FL or LBD, 100 nM streptavidin-APC, 3 nM Eu-labeled anti-GST 
antibody and 600 nM bSRC-1 M2 in 50 mM Tris pH 8.0, 50 mM KCL, 1 mM EDTA, 1 
mM DTT and 1 mg / ml BSA. All agonists were solubilized in DMSO. Agonist titrations 
were prepared in DMSO at 100x assay concentration. Prior to addition of the assay mix, 
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1 μl of agonist titration was dispensed to the 96-well assay plate (final DMSO conc. 1%). 
Plates were mixed well by pipetting and handled identically as described above. 
 
Preparation of stable reporter cell line 
pG5luc, GenBank accession number AF264724, is a reporter vector containing 
the Gal4 response element upstream from a fire fly luciferase reporter gene (Promega). 
The plasmid was converted into a stable reporter plasmid by cloning a neomycin 
resistance gene at the BamHI (2142) / SalI (2148) sites. Wild type HEK293 (ATCC# 
CRL-1573) cells were transfected with the pG5luc+neo plasmid using lipofectamine 
according to the manufacturer’s instructions. Single clones were selected using 800 μg 
/ml geneticin. Transformed cells were grown in DMEM with 4.5 g / L glucose and 25 
mM Hepes supplemented with 10 % charcoal stripped fetal bovine serum, penicillin-
streptomycin and glutamine. Cells were maintained at 37°C in a 5 % CO2 humidified 
incubator.  
 
Preparation of Gal4 DBD PPARα FL and LBD chimeras 
pBIND vector, AF264722, contains a MCS downstream from the yeast Gal4 
DBD (Promega). The pBind vector was converted into a Gateway destination vector 
through the insertion of Reading Frame B (rfb) at the EcorV site (1594) as per 
manufacturer’s instructions. The pENTR: PPARα FL / LBD plasmids were then 
recombined with the converted destination vector pBIND: rfb using LR clonase. All 
constructs were 5’ sequence confirmed for correct orientation of gene (described 
previously in section 2.2.4). 
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Gal4 reporter assay- Agonist titrations 
The pG5luc + neo HEK293 stables were batch transfected with either pBind: 
hPPARα or hPPARα LBD plasmid at 200 ng /μl using lipofectamine as per 
manufacturer’s protocol. The cells were plated at a concentration of 5 x 105 cells per well 
into black-well clear bottom tissue culture treated plates. The transfected cells were 
incubated for 24 hours, after which the media was replaced with 100 μl of fresh media. 
Either DMSO or agonists were added to the cells (0.1 % DMSO final). The cells were 
returned to the incubator for another 24 hours. Luciferase measurements were conducted 
using Promega’s Bright GLO reagents. All media was removed from the wells and a 1:1 
mixture of phenol red free media and Bright GLO substrate were added at a final volume 
of 200 μl. The plates were placed on an orbital shaker for 2 minutes to aid in cell lysis 
then read on a Perkin Elmer Victor V using the factory settings for luminescence 
readings. 
 
3.3 Results and Discussion 
PPARα FL and LBD display differences in coactivator recruitment 
PPARα FL and LBD were tested in the coactivator recruitment assay to determine 
their relative affinity and total fluorescence signal for the three coactivator peptides. The 
measurement of coactivator recruitment is determined by the amount of energy 
transferred from europium (λex 335 / λem 615) to allophycocyan (λex 615 / λem 665) 
[290]. Figure 11 illustrates the transfer of energy between these two molecules when they 
are brought within close proximity of each other. This event occurs when the receptor 
assumes a suitable conformation that allows for binding of the coactivator LXXLL 
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sequence [291]. Considering that the FL and LBD receptor could potentially assume 
different conformations based on the inclusion or exclusion of the highly structured N-
terminal domain, it was important to determine whether this would convert into a 
measurable difference between the coactivator binding affinity and / or total fluorescence 
of the assay.  Titrations for all assay components were performed for both full length and 
LBD construct to ensure that maximal interaction signals could be generated.   
NR-LBD
tagY
Eu
SA APC
ligand
B
biotinylated peptide
Eu
337 nm
620 nm
665 nm
 
Figure 11. Illustration of Homogeneous Time-Resolved Fluorescence (HTRF) Assay for Detection of 
Coactivator Recruitment. Ligand activation of the labeled receptor results in conformational changes 
allowing for recruitment of coactivator peptides. The interaction between the labeled coactivator peptide 
and tagged receptor are detected by monitoring changes in energy transfer levels between Eu and APC. 
 
 
Coactivator recruitment levels for the FL receptor, in the absence of ligand, are 2-
3 fold greater than those observed for the LBDA. This increase in constitutive coactivator 
recruitment by FL PPARα is consistent for all three coactivator peptides tested. High 
levels of constitutive recruitment of coactivator peptides by PPARs have been reported 
  103 
previously using a tagged PPAR LBD [213, 292]. Since the FL receptor includes the 
complete LBD, it would be reasonable to expect similar constitutive interactions to occur. 
However the level of increase in coactivator recruitment for the FL PPARα was 
unexpected, and may suggest interactions with regions outside the LBD.  
Ligand-induced coactivator recruitment increases the total level of fluorescent 
signal for both constructs. Two of the coactivator peptides, bCBP and bPGC-1, show 
similar levels of recruitment for both FL and LBD constructs. bSRC-1 M2 peptide is 
recruited at a level ~ 5 fold greater for FL PPARα than LBD in the presence of saturating 
amounts of ligand (GW7647) (Figure 12). Since the previous experiments were 
conducted using saturating concentrations for all assay components, including coactivator 
peptide, the observed increase in fluorescence for the FL construct is most likely due to a 
favorable receptor conformation which allows a more efficient energy transfer between 
Eu and APC rather than an actual increase in affinity for the coactivator peptides. To rule 
out the possibility of increased affinity due to additional coactivator-binding sites in the 
N-terminus, titrations were performed for each coactivator and binding constants were 
determined.   
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Figure 12. Levels of Constitutive and Ligand-Induced Coactivator Recruitment Obtained in Cell-
Free Assays for Each Construct Using Three Different Coactivators. Each bar is the average of three or 
more determinations, and the error bars signify the standard deviation. The agonist employed for induction 
of coactivator recruitment is GW7647 at 10 μM. Each data point is the mean of a duplicate, and the error 
bars represent the standard deviation. 
 
 Figure 13 shows the titration of the coactivator peptide bSRC-1 M2 in the 
presence of the agonist GW7647 with both receptor constructs. All data sets were fit to a 
single site saturation equation, and the Kd determined (Table 12) The affinity of the FL 
receptor for bCBP is 115 nM , bPGC-1 is 83 nM and bSRC-1 M2 is 73.9 nM. These Kd 
values are 2- fold (bCBP and bPGC-1) and 5-fold less, respectively, than those observed 
for LBD receptor. The hill coefficient for all the coactivator titrations were determined to 
be 1, suggesting binding of only one coactivator peptide per receptor. It appears unlikely 
that coactivator binding is occurring in regions other than the LBD.   
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Figure 13. Change in the Fluorescence Ratio as a Function of the Coactivator Peptide bSRC-1 M2. 
The assay was conducted at room temperature and pH 7 under saturating conditions for Eu antibody, 
Streptavidin-APC and receptor. The agonist employed for induction of coactivator recruitment is GW7647 
at 10 μM. Each data point is the mean of a duplicate, and the error bars represent the standard deviation. 
 
 
 
Table 13. Equilibrium Constants for Coactivator Peptide Binding to PPARα FL and LBD. 
 
 Kd (nM) 
Coactivator peptide PPARα FL  PPARα LBD 
bSRC-1 M2 73.9  +/- 1.4  364.5  +/- 2.7 
bCBP 115.0 +/- 5.9  246.5  +/- 20.3 
bPGC-1 83.0  +/- 4.6  237.6  +/- 23.5 
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Although there is no evidence of direct binding of our panel of coactivators to the 
AF-1, other coactivators have been found to not only bind directly but bind exclusively to 
the AF-1. A binding site for the coactivator peroxisomal enoyl-CoA hydratase/ 3-
hydroxyacyl-CoA dehydrogenase (bifunctional enzyme, BFE) has been mapped to the 
AF-1 region of the PPARα receptor and has been found to act constitutively [293]. GST-
pull down experiments performed by Juge-Aubrey et al. provide no evidence that 
coactivators involved in ligand-induced activation of PPARα , to include our panel,  are 
also bound by the AF-1 region. This however does not exclude the need for nonspecific 
interaction of the obligate AF-2 coactivators with the N-terminal AF-1 domain for high 
affinity binding to occur, as our data suggests. It has been determined that 
phosphorylation of the AF-1 is required for ligand-independent coactivator recruitment 
for some nuclear receptors including estrogen receptor β and PPARα [294, 295]. 
However, other member of the PPAR family, such as PPARγ, do bind supposed ligand-
dependent coactivators in the AF-1 region without the requirement of phosphorylation 
[296].  While the data analysis from binding experiments suggests that there are no 
additional binding sites for the panel of coactivators in the AF-1 domain, further 
investigation into potential interactions is warranted.  
 
PPARα FL and LBD display differences in reporter gene expression 
In order to determine if the difference in affinity of coactivator peptides in the 
HTRF assay would result in a direct effect on gene transcription levels, both constructs 
were analyzed in a Gal4 reporter assay. Briefly, Gal4 DBD fusions were created for both 
FL and LBD PPARα.  Either the FL or LBD constructs were batch transfected with the 
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reporter vector pG5 luc+, containing the fire fly luciferase gene downstream from the 
Gal4 response element. Any observed increase in luminescence signal would be a direct 
result of PPARα activation. Levels of luciferase transcription, in the absence of ligand, 
were found to be 2-3 fold higher for the FL receptor than the LBD under similar 
conditions.  It was also determined that the FL receptor displayed a much stronger 
transcriptional activation than LBD in the presence of the agonist ciprofibrate (Figure 
14). The increase in transcriptional activation of FL receptor was consistent for all 
agonists tested, and may arise from the FL PPARα receptor assuming a more suitable 
conformation for assembly of enzymes and coactivators involved in transcription. Our 
results are similar to previous observations concerning the additive role of the mouse 
PPARα AF-1 domain in gene transcription [297]. The increase in transactivation may 
also be due in part to the increase in affinity for coactivators that was observed in the 
coactivator recruitment assay. 
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Figure 14. Change in Luminescence as a Function of the Concentration of Ciprofibrate for the 
Gal4DBD-PPARα LBD and FL Receptors in the Cell-Based Reporter Assay.  Background 
luminescence was subtracted (DMSO) from each point, and contributed less than 20% of the total signal.  
Each data point is the mean of two determinations, and the error bars are the standard deviation. 
 
 
PPARα FL and LBD show no difference in affinity for agonists 
Figure 15 shows agonist titrations in the coactivator recruitment assay for both 
PPARα FL and LBD constructs. The figure is a good illustration of the benefit obtained 
from utilizing the FL receptor in the coactivator recruitment assay. In addition to 
achieving greater assay signal, the agonist affinity remains consistent between the two 
constructs. Table 14 lists Kd values in cell free and and EC50 values for cell based assays 
obtained for a panel of agonists. The data indicates that there is no significant difference 
in agonist Kd and EC50 values between constructs.  
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Figure 15. Change in Fluorescence as a Function of Concentration of Agonist in the Coactivator 
Recruitment Assay.  A total of four ligands were titrated against both full length and ligand binding 
domain constructs. Assays were conducted under saturating conditions for all components with the 
exception of agonist. Coactivator peptide used in assays is bSRC-1 M2. All values corrected for 
background fluorescence which never exceeded 20% of the total signal. Each data point is the mean of 
three determinations and the error bars represent standard deviation. 
 
 
 
 
 
Table 14. EC50 Values for Agonist Activity of Various Ligands Vs. PPARα  FL and LBD 
                                  Coactivator recruitment Kd (μM)         Gal4 reporter EC50 (μM) 
Agonist  PPARα FL      PPARα LBD       PPARα FL   PPARα LBD 
ciprofibrate  1.4  ±  0.03              2.2  ±  0.14                 6.9  ±  1.7               5.2  ±  1.8 
WY,14643  1.6  ± 0.16              2.3  ±  0.28                 15.1  ±  4.3             16.5  ±  4.4 
GW7647             4x10-3 ±  0.3           5x10-3 ±  0.1          2x10-3  ±  0.4          5x10-3 ± 2.0       
Bezafibrate  4.8  ±  0.4                7.2  ± - 0.8             15.4  ±  1.1            17.6  ±  9.0 
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In summary, PPARα FL and LBD constructs do display differences in agonist 
efficacy in both cell free and cell based assays. They do not, however, display differences 
in agonist affinity. The increase in agonist efficacy for FL PPARα is consistent for all 
agonists tested. In the cell free assay, FL PPARα was shown to have a higher affinity for 
coactivators along with significantly higher assay signal when compared to the LBD 
construct. Upon analysis of the data, it was determined that the increase in assay signal 
was not a direct result of the increased affinity for coactivators. It appears as thought FL 
PPARα is able to adopt a more favorable conformation for efficient energy transfer 
between fluorescence groups. The increased fluorescence from these conformational 
differences results in a more robust assay system for analyzing agonists.  
The higher binding affinity for coactivators that was observed for the FL PPARα 
in the cell free system may explain the differences in gene expression levels between FL 
and LBD in the Gal4 assay system. Increased affinity for coactivators would most likely 
convert into increased efficiency in assembly of transcription machinery, resulting in 
higher levels of gene expression. Therefore, the FL PPARα construct seems to be more 
suitable for use in receptor assays due to the increase transcription and fluorescence 
signal obtained and the overall similarity to the native receptor.  
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